CO N FI D E N TI A L  
ST U D Y D R U G :  H 3 B -6 5 4 5  
PR O T O C O L AM E N D M E N T 9:   2 9  AU G 2 0 2 2  P a g e 1 of 1 6 0  A P h a s e 1- 2 m ulti c e nt e r, o p e n -l a b el t ri al of H 3 B -6 5 4 5, a c o v al e nt a nt a g o ni st 
of e st r o g e n r e c e pt o r al p h a, i n w o m e n wit h l o c all y a d v a n c e d o r m et a st ati c 
e st r o g e n r e c e pt o r -p o siti v e, H E R 2 n e g ati v e b r e a st c a n c e r  
  
S P O N S O R  S T U D Y  P R O T O C O L  N U M B E R:   H 3 B -6 5 4 5 -A 0 0 1 -1 0 1  
I N D  N U M B E R:  
E U D R A C T  N U M B E R:  1 3 3, 2 8 2  
2 0 1 8 -0 0 0 5 7 0 -2 9  
S T U D Y  D R U G:  H 3 B -6 5 4 5  
 
S P O N S O R:  Ei s ai I n c.  
2 0 0 M etr o  B o ul e v ar d  
N utl e y , N J 0 7 1 1 0  
U S A  
 
  
S T U D Y  C H A I R:   
S ar a h C a n n o n R e s e ar c h I n stit ut e  
1 1 0 0 C h arl ott e A v e n u e, S uit e 8 0 0  
N a s h vill e, T N 3 7 2 0 3  
U S A  
1- 8 7 7 -M Y - 1- S C RI  
 P P D 
 
CO N FI D E N TI A L  
ST U D Y D R U G :  H 3 B -6 5 4 5  
PR O T O C O L AM E N D M E N T 9:   2 9  AU G 2 0 2 2  P a g e 2 of 1 6 0   
D A T E  F I N A L:  1 9 M a y 2 0 1 7  
A M E N D M E N T  N U M B E R  1 
A M E N D M E N T  N U M B E R  2 
A M E N D M E N T  N U M B E R  3 
A M E N D M E N T  N U M B E R  4 
A M E N D M E N T  N U M B E R  5 
A M E N D M E N T  N U M B E R  6 
A M E N D M E N T  N U M B E R  7 
A M E N D M E N T  N U M B E R  8 
A M E N D M E N T  N U M B E R  9 
  C CI 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 4 of 160 CLINICAL STUDY PRINCIPAL INVESTIGATOR SIGNATURE FORM  
A Phase I -II multicenter, open- label tri al  of H3B -6545, a covalent antagonist 
of estrogen receptor alpha, in women with locally advanced or metastatic 
estrogen receptor -positive, HER2 negative breast cancer 
  
SPONSOR  STUDY  PROTOCOL  NUMBER:  H3B -6545- A001 -101 
IND  NUMBER:   
EUDRACT NUMBER:  133,282  
2018 -000570- 29 
DATE  FINAL:  19 May 2017 
AMENDMENT  NUMBER  9: 29 Aug 2022 
By signing this protocol acceptance page, I confirm I have read, understand, and agree to conduct the 
study in accordance with the current protocol.  
 
  __________________________ __________________________         ______________  
Principal Investigator Name  
<<Insert Site Name and ID info as 
applicable>>  
<<Insert Site Location >> 
 Principal Investigator Signature  
 Date  
 
 
CO N FI D E N TI A L  
ST U D Y D R U G :  H 3 B -6 5 4 5  
PR O T O C O L AM E N D M E N T 9:   2 9  AU G 2 0 2 2  P a g e 5 2  of 1 6 0  P R O T O C O L S Y N O P S I S  
Titl e of St u d y:  A P h a s e I -II m ulti c e nt er, o p e n -l a b el tri al of H 3 B -6 5 4 5, a c o v al e nt a nt a g o ni st of e str o g e n 
r e c e pt or al p h a, i n w o m e n wit h l o c all y a d v a n c e d or m et a st ati c e str o g e n r e c e pt or -p o siti v e, 
H E R 2 n e g ati v e br e a st c a n c er  
S p o n s o r St u d y 
N u m b e r s:  H 3 B -6 5 4 5 -A 0 0 1 -1 0 1  
S p o n s o r:  Ei s ai,  I n c.  
St u d y D u r ati o n:  T h e t ot al d ur ati o n of t h e st u d y i s pl a n n e d t o b e fi v e ( 5) y e ar s.  P h a s e of 
St u d y:   1-2 
St u d y Sit e s:  A p pr o xi m at el y 4 sit e s pl a n n e d f or P h a s e 1 a n d a p pr o xi m at el y   sit e s f or P h a s e 2.  
N u m b e r of 
S u bj e ct s:   U p t o a p pr o xi m at el y 1 7 0 s u bj e ct s wit h l o c all y a d v a n c e d or m et a st ati c br e a st c a n c er ar e 
pl a n n e d t o b e e nr oll e d i n t hi s st u d y.  
O bj e cti v e s:  P h a s e 1  
T h e pri m ar y o bj e cti v e of t h e P h a s e 1 p orti o n of t hi s st u d y i s t o:  
● D et er mi n e t h e m a xi m u m t ol er at e d d o s e ( M T D) a n d/ or t h e r e c o m m e n d e d P h a s e 2 
d o s e ( R P 2 D) of H 3 B -6 5 4 5 i n w o m e n wit h l o c all y a d v a n c e d or m et a st ati c e str o g e n 
r e c e pt or ( E R) -p o siti v e, h u m a n e pi d er m al gr o wt h f a ct or r e c e pt or -2 ( H E R 2) -
n e g ati v e br e a st c a n c er.  
T h e s e c o n d ar y o bj e cti v e s of t h e P h a s e 1 p orti o n of t hi s st u d y ar e t o:  
● E v al u at e t h e s af et y a n d t ol er a bilit y of H 3 B -6 5 4 5 a s a si n gl e a g e nt a d mi ni st er e d 
or all y o n c e d ail y ( Q D) o v er a 2 8 -d a y c y cl e i n t hi s s u bj e ct p o p ul ati o n  
● C h ar a ct eri z e t h e pl a s m a p h ar m a c o ki n eti c s ( P K) of H 3 B -6 5 4 5.  
● E sti m at e t h e effi c a c y of H 3 B -6 5 4 5 i n t er m s of r e s p o n s e r at e, d ur ati o n of r e s p o n s e 
( D o R), di s e a s e c o ntr ol r at e ( D C R), pr o gr e s si o n -fr e e s ur vi v al ( P F S), a n d o v er all 
s ur vi v al ( O S).  
T h e e x pl or at or y o bj e cti v e s of t h e P h a s e 1 p orti o n of t hi s st u d y ar e t o:  
P h a s e 2  
T h e pri m ar y o bj e cti v e of t h e P h a s e 2 p orti o n of t hi s st u d y i s t o:  
● E sti m at e t h e effi c a c y of H 3 B -6 5 4 5 i n t er m s of b e st o v er all r e s p o n s e r at e, D o R, 
D C R, cli ni c al b e n efit r at e, P F S, a n d O S i n all s u bj e ct s wit h E R -p o siti v e H E R 2 -
n e g ati v e br e a st c a n c er a n d i n t h o s e wit h a n d wit h o ut E R α m ut ati o n ( E R α M U T) 
(i n cl u di n g a cl o n al e str o g e n r e c e pt or  1 [ E S R 1] Y 5 3 7 S m ut ati o n)  
T h e s e c o n d ar y o bj e cti v e s of t h e P h a s e 2 p orti o n of t hi s st u d y ar e t o:  
● F urt h er c h ar a ct eri z e t h e s af et y of H 3 B -6 5 4 5 i n t hi s s u bj e ct p o p ul ati o n  
● F urt h er c h ar a ct eri z e t h e P K of H 3 B -6 5 4 5.  At l e a st s p ar s e P K s a m pl e s will b e 
c oll e ct e d fr o m all s u bj e ct s o n st u d y.  
● E v al u at e t h e eff e ct of a hi g h -f at m e al o n t h e r el ati v e bi o a v ail a bilit y of H 3 B -6 5 4 5.  
● A s s e s s t h e eff e ct of H 3 B -6 5 4 5 o n s er u m b o n e t ur n -o v er m ar k er s, n a m el y b o n e -
s p e cifi c al k ali n e p h o s p h at a s e ( B S A P; f or o st e o cl a st m et a b oli s m), a mi n o -t er mi n al C CI C CI 
 
CO N FI D E N TI A L  
ST U D Y D R U G :  H 3 B -6 5 4 5  
PR O T O C O L AM E N D M E N T 9:   2 9  AU G 2 0 2 2  P a g e 5 4  of 1 6 0  d et er mi n e d b y c e ntr al l a b or at or y a s s e s s m e nt pri or t o si g ni n g t h e m ai n st u d y c o n s e nt. 
S e e S e cti o n 5. 2 . 
U n d er A m e n d m e nt 8, a p pr o xi m at el y   s u bj e ct s will b e e nr oll e d  t o all o w f or 
a p pr o xi m at el y   r e s p o n s e e v al u a bl e s u bj e ct s.  
I n cl u si o n 
C rit e ri a:  S u bj e ct s m u st m e et t h e f oll o wi n g crit eri a i n or d er t o b e i n cl u d e d i n t h e r e s e ar c h st u d y:  
1.  Pr e s cr e e ni n g: S u bj e ct s m u st h a v e cl o n al E S R 1 Y 5 3 7 S m ut ati o n at A F ≥ 0. 5 %, i n t h e 
a b s e n c e of E S R 1 D 5 3 8 G at A F ≥ 0. 5 %, a s d et er mi n e d at pr e s cr e e ni n g b y a S p o n s or -
d e si g n at e d c e ntr al l a b or at or y fr o m a N u cl ei c A ci d s W h ol e Bl o o d ( pl a s m a cf D N A) 
s a m pl e.  
2.  S u bj e ct h a s si g n e d i nf or m e d c o n s e nt f or m (I C F) b ef or e a n y tri al -r el at e d a cti viti e s 
a n d a c c or di n g t o l o c al g ui d eli n e s.  M ai n I C F m a y o nl y b e si g n e d o n c e p o siti v e 
m ut ati o n st at u s i s c o nfir m e d b y a s p o n s or -d e si g n at e d  c e ntr al l a b or at or y, u nl e s s pri or 
a ut h ori z ati o n h a s b e e n r e c ei v e d b y t h e S p o n s or, b a s e d o n l o c al m ut ati o n a n al y si s.   
3.  O nl y f e m al e s ar e eli gi bl e.  M e n o p a u s al st at u s:  
 
− P o st m e n o p a u s al d efi n e d b y:  
 
a)  Pri or bil at er al o o p h or e ct o m y,  
b)  A g e ≥ 6 0 y e ar s, or  
c)  A g e < 6 0 y e ar s a n d a m e n orr h e a f or 1 2 or m or e m o nt h s (i n t h e a b s e n c e of 
c h e m ot h er a p y, t a m o xif e n, t or e mif e n e, or o v ari a n s u p pr e s si o n); or a 
f olli cl e -sti m ul ati n g h or m o n e v al u e > 4 0  mI U/ m L a n d a n e str a di ol v al u e 
< 4 0  p g/ m L ( 1 4 0  p m ol/ L) or i n p o st m e n o p a u s al r a n g e s p er  l o c al r ef er e n c e 
r a n g e s  
Or  
− Pr e m e n o p a u s al or p eri m e n o p a u s al c o n c urr e ntl y gi v e n a l ut ei ni zi n g  h or m o n e -
r el e a si n g h or m o n e ( L H R H) a g o ni st st arti n g at l e a st 4 w e e k s b ef or e t h e st art of 
tri al t h er a p y a n d i s pl a n n e d t o c o nti n u e L H R H d uri n g t h e st u d y.    
4.  S u bj e ct h a s a hi st ol o gi c all y a n d/ or c yt ol o gi c all y c o nfir m e d di a g n o si s of E R -p o siti v e 
br e a st c a n c er b y l o c al l a b or at or y.  
5.  S u bj e ct h a s H E R 2 -n e g ati v e br e a st c a n c er a s d efi n e d b y A m eri c a n S o ci et y f or 
Cli ni c al O n c ol o g y C oll e g e of A m eri c a n P at h ol o gi st s g ui d eli n e s ( W olff et al. 2 0 1 3 ).  
6.  S u bj e ct m u st h a v e pr o gr e s s e d o n t h e m o st r e c e nt t h er a p y.   
7.  Pri or t h er a p y f or br e a st c a n c er i n t h e a d v a n c e d/ m et a st ati c s etti n g m u st h a v e i n cl u d e d 
a mi ni m u m of : 
a)  t w o pri or h or m o n al t h er a pi e s, or  
b)  o n e pri or h or m o n al t h er a p y a n d o n e pri or c h e m ot h er a p y r e gi m e n, or  
c)  o n e pri or h or m o n al t h er a p y a n d a C D K 4/ 6 i n hi bit or.   
N ot e: S u bj e ct s m a y h a v e r e c ei v e d tr e at m e nt f or br ai n m et a st a s e s, b ut m u st b e 
n e ur ol o gi c all y st a bl e, c o m pl et e d r a di ot h er a p y a n d off c orti c o st er oi d s f or at l e a st o n e 
m o nt h pri or t o st arti n g tri al t h er a p y.  
N ot e:  S u bj e ct s e nr oll e d u n d er A m e n d m e nt 6 (or s u b s e q u e nt a m e n d m e nt s) m u st 
h a v e r e c ei v e d pri or t h er a p y, i n cl u di n g at l e a st o n e pri or h or m o n al t h er a p y a n d a 
C D K 4/ 6 i n hi bit or.  U p t o o n e pri o r c h e m ot h er a p y i n t h e m et a st ati c s etti n g i s all o w e d.  
8.  S u bj e ct m u st h a v e at l e a st o n e bi o p si a bl e l e si o n i n t h e P h a s e 1 p orti o n.  I n t h e P h a s e 
2 p art of t h e tri al, s u bj e ct s m u st h a v e eit h er  C
CI C
CI 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 55 of 160 a) at least one measurable lesion as per Response Evaluation Criteria in Solid 
Tumors (RECIST) 1.1, or  
b) at least one predominantly lytic bone lesion.   
Note:  Subjects enrolled under Amendment 6 (or subsequent amendments) must have at least one measurable les ion as per RECIST 1.1.  
9. Subject must be willing to undergo tumor biopsies prior to treatment and on Cycle 2  
Day 1.  In the Phase 2 part of the trial, subjects with bone -only disease, or those for 
whom a biopsy is contra -indicated, may opt out of providing tumor biopsies 
following investigator concern and direct discussion and approval from the Sponsor.   
Note: A subset of subjects in Phase 2 will be required to provide tumor tissue until 
tumor pairs have been collected from at least 15 subjects with ERα
WT and 15 
subjects with ERαmut (determined retrospectively by Sponsor -designated central 
laboratory test).   
Note:  For subjects enrolled under Amendment 6 (or subsequent amendments), a 
recent archival tumor tissue obtained within 6 months prior to enrollment or a fresh tumor biopsy must be provided. A second biopsy after initiating trial therapy is not 
required.  
10. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 
0 or 1.  
11. Subject has adequate bone marrow and organ function, as defined by the following laboratory values:  
● Absolute neutrophil count ≥1.5 × 10
9/L 
● Platelets ≥100 × 109/L 
● Hemoglobin ≥9.0 g/dL (may have been transfused).  
● Potassium, sodium, calcium (corrected for serum albumin) and magnesium 
<CTCAE Grade 2  
● Cockcroft -Gault based creatinine clearance ≥35 mL/min 
● Serum albumin ≥3.0 g/dL (≥30 g/L)  
● In the absence of liver metastases, alanine aminotransferase (AST) and aspartate 
aminotransferase (ALT) should be below 3.0 × ULN.  If the subject has liver 
metastases,  ALT and AST should be below 5.0 × ULN.  
● Total serum bilirubin <ULN. For subjects with documented Gilbert’s syndrome, 
total serum bilirubin <2.5 × ULN  
12. Age ≥18 years  
13. Willingness and ability to comply with study and follow -up procedures  
14. Ability to understand  the nature of this study and give written informed consent  
Exclusion 
Criteria:  Subjects who meet any of the following criteria will be excluded from study entry:  
1. Subject with bone -only disease (Phase 1 only).   
2. Phase 2 subjects may have predominantly lytic bone -only disease.   
Note:  Subjects enrolled under Amendment 6 (or subsequent amendments) must 
have at least one measurable lesion as per RECIST 1.1.  
3. Subject with inflammatory breast cancer.  
4. Subject has received more than one prior chemotherapy regimen for metastatic 
disease (Phase 2 only).  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 56 of 160 5. Subject has had prior antineoplastic therapy within 14 days prior to starting study 
drug.   
6. Subject is currently r eceiving or has received systemic corticosteroids ≤2 weeks 
prior to starting study drug, or has not fully recovered from side effects of such treatment.  
Note: The following uses of corticosteroids are permitted: single doses, topical applications (eg , for rash), inhaled sprays (eg , for obstructive airways diseases), eye 
drops or local injections (eg, intra-articular).  
7. Subject has received radiotherapy ≤4 weeks or limited field radiation for palliation ≤2 weeks prior to starting study d rug, and who has not recovered to Grade 1 or 
better from related side effects of such therapy (with the exception of alopecia) and/or for whom ≥30% of the bone marrow was irradiated.  
8. Major surgical procedures ≤14 days of beginning study drug, or minor surgical 
procedures ≤7 days, or has not recovered from major side effects. No waiting 
required following port -a-cath placement.   
9. Subject has active cardiac disease or a history of cardiac dysfunction, including any of the following: 
● History of angina pectoris, symptomatic pericarditis, or myocardial infarction 
within 12 months prior to study entry  
● History of documented congestive heart failure (New York Heart Association functional classification III or IV)  
● Documented cardiomyopathy  
● Subject has a left ventricular ejection fraction <50% as determined by multiple - 
gated acquisition (MUGA) scan or echocardiogram.  
● History of any cardiac arrhythmias, eg, ventricular, supraventricular, nodal 
arrhythmias, or conduction abnormality, in the previous 12 months  
● A prolonged QTcF interval >450 msec as demonstrated by a repeated ECG; a 
history of risk factors for Torsade de pointes (eg, heart failure, hypokalemia, and family history of long QT syndrome); or the use of concomitant medications that 
prolonged the QTcF i nterval  
● Subject has a resting pulse rate <60 bpm  
10. Subject has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of H3B -6545 (eg, ulcerative diseases, uncontrolled 
nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).  
11. Subject has a known hypersensitivity to any of the excipients of H3B -6545.  
12. Subject has a known history of human immunodeficiency virus infect ion or hepatitis 
C virus, or requires treatment with protease inhibitors (testing not mandatory).  
13. Subject has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, contraindicate subject participation  in the 
clinical study (eg , chronic pancreatitis, active hepatitis, etc).  
14. Subject received in the 7 days prior to the administration of study drug or is currently receiving any of the following medications (see Appendix H and 
Appendix I for details): 
a. Known strong inducers or inhibitors of cytochrome P450 (CYP) 3A4 or P -
glycoprotein  
b. Medications that have a known risk to prolong the QT interval or induce Torsades de Pointes.  
c. Medications that have a narrow therapeutic window and are predominantly 
metaboli zed through CYP2C8, CYP2C9, CYP2C19, or CYP3A4  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 57 of 160 d. Medications that have a narrow therapeutic window and are breast cancer 
resistance protein substrates  
e. Herbal preparations/medications; these herbal medications include, but are not 
limited to, St. John’s wort,  kava, ephedra (ma huang), gingko biloba, 
dehydroepiandrosterone, yohimbe, saw palmetto, and ginseng  
15. Any adverse event related to previous therapies for breast cancer that has not resolved to ≤Grade 1.  
16. Females who are breastfeeding or pregnant at Screening or Baseline (as documented 
by a positive beta -human chorionic gonadotropin [ß -hCG] (or human chorionic 
gonadotropin [hCG]) test with a minimum sensitivity of 25 IU/L or equivalent units of ß-hCG [or hCG]).  A separate baseline assessment is requi red if a negative 
screening pregnancy test was obtained more than 72 hours before the first dose of 
study drug.  
17. Females of childbearing potential who:  
● Had unprotected sexual intercourse within 30 days before study entry and who do 
not agree to use a highly effective method of contraception (eg , total abstinence, 
an intrauterine device, a double -barrier method [such as condom plus diaphragm 
with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study 
period or for 28  days after study drug discontinuation.  
● Are currently abstinent, and do not agree to use a double -barrier method (as 
described above) or refrain from sexual activity during the study period or for 28 days a fter study drug discontinuation.  
● Are using hormonal contraceptives but are not on a stable dose of the same 
hormonal contraceptive product for at least 4 weeks before dosing and who do not 
agree to use the same contraceptive during the study or for 28 days  after study 
drug discontinuation  
All females will be considered to be of childbearing potential unless they are 
postmenopausal [amenorrheic for at least 12  consecutive months, in the appropriate 
age group, and without other known or suspected cause] or have been sterilized 
surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, 
all with surgery at least 1  month before dosing]).  
18. Alcohol dependency within 6 months before study entry.  
19. Subject has a concurrent malignancy or malignancy within 3 years of enrollment, 
with the exception of adequately treated basal or squamous cell carcinoma, non -
melanomatous skin cancer, or curatively resected cervical cancer.  
20. Psychological, familial, sociological, or geographical conditions that  do not permit 
compliance with the protocol.   
21. Subjects with advanced, symptomatic visceral spread, that are at risk of life-
threatening complications in the short term.  
22. Subjects with abnormal coagulation profiles, or any history of coagulopathy within 
6 months prior to the first dose of study drug, including history of deep vein 
thrombosis (DVT) or pulmonary embolism.  
Note: subjects (except pre/perimenopausal women) with  adequately treated 
catheter -related venous thrombosis occurring more than one month prior to the first 
dose of study drug will be allowed to participate.  
23. Prothrombin time/international normalized ratio (INR) >1.5 times the upper limit 
of normal (ULN) or o utside therapeutic range if receiving anticoagulation that 
would affect the prothrombin time/INR.  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 60 of 160 LIST OF ABBREVIATIONS  
AE Adverse event  
AESI  Adverse event of special interest  
AF Allelic frequency  
ALP  Alkaline phosphatase  
ALT  Alanine aminotransferase  
AR Adverse reaction  
AST  Aspartate aminotransferase  
AUC  Area under the curve  
ß-hCG  beta-human chorionic gonadotropin  
BCRP  Breast cancer resistance protein  
BP Blood pressure  
BSAP  Bone -specific alkaline phosphatase  
CBC  Complete blood count  
cfDNA  Cell-free DNA  
CFR  Code of Federal Regulations  
CI Confidence interval  
CL/F  Apparent total body clearance following oral administration  
Cmax Maximum observed plasma concentration  
CMP  Comprehensive metabolic profile  
CR Complete response  
CRF  Case report form  
CRO  Contract research organization  
CT Computed tomography  
CTA  Clinical trial agreement  
CTX  C-terminal cross -linking telopeptide of type 1 collagen  
CYP  cytochrome P450  
DCR  Disease control rate  
DDI Drug -drug interaction  
DHEA  Dehydroepiandrosterone  
DLT  Dose -limiting toxicity  
DNA  Deoxyribonucleic acid  
DoR  Duration of response  
EC Ethics Committee  
EC 50 Half-maximal exhibitory concentration  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic case report form  
EOT  End-of-Treatment  
ER Estrogen receptor  
ERα Estrogen receptor alpha  
ERαWT  Estrogen receptor alpha wild -type 
ERαmut Estrogen receptor alpha mutant  
ESR1  Estrogen receptor 1 gene  
FAS Full Analysis Set  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 61 of 160 FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GI Gastrointestinal  
GLP  Good Laboratory Practice  
HED  Human equivalent dose  
HER2  Human epidermal growth factor receptor -2 
HNSTD  Highest non -severely toxic dose  
HR Heart rate  
IB Investigator’s Brochure  
ICF Informed consent form  
ICH International Conference on Harmonisation  
INR International normalized ratio  
IRB Institutional Review Board  
ISF Investigatory study file  
LHRH  Luteinizing hormone -releasing hormone  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  Magnetic resonance imaging  
MRSD  Maximum recommended starting dose  
MTD  Maximum tolerated dose  
MUGA  Multiple -gated acquisition  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for 
Adverse Events  
ORR  Objective response rate  
OS Overall survival  
PD Pharmacodynamic(s)  
PFS Progression -free survival  
P-gp P-glycoprotein  
PG Pharmacogenetic(s)  
PHI Protected health information  
PI Principal Investigator  
PINP  Amino -terminal propeptide of type 1 collagen  
PK Pharmacokinetic(s)  
PO Orally/by mouth  
PS Performance status  
PT/PTT  Prothrombin time/partial thromboplastin time  
QD Once daily  
QRS interval  Q, R, and S heart waves shown on electrocardiogram  
QTc QT interval corrected for heart rate  
QTcF  QT interval corrected for heart rate using Fridericia’s formula  
Racc Accumulation ratio  
RECIST  Response Evaluation Criteria in Solid Tumors  
RES Response -Evaluable Set  
RNA  Ribonucleic acid  
RP2D  Recommended Phase 2 dose  
RR Respiratory rate  
SAE  Serious adverse event  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 62 of 160 SAR  Suspected adverse reaction  
SD Stable disease  
SOC  System Organ Class  
SRC  Safety Review Committee  
STD 10 Severely toxic dose in 10% of animals  
t½  Terminal elimination half -life 
TEAE  Treatment -emergent adverse event  
tmax Time of maximum observed plasma concentration  
TSH  Thyroid -stimulating hormone  
ULN  Upper limit of normal  
Vz/F Apparent volume of distribution during terminal phase  
WBC  White blood count  
WHO DD  World Health Organization Drug Dictionary  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 63 of 160 TABLE  OF CONTENTS  
H3B-6545-A001- 101 PROTOCOL SUMMARY OF CHANGES  ......................................... 5  
PROTOCOL SYNOPSIS ....................................................................................................... 52  
1. INTRODUCTION  ................................................................................................. 69  
1.1 Background ........................................................................................................... 69  
1.2 Role of the Estrogen Pathway in Breast Cancer .................................................... 69  
1.3 Role of H3B-6545 in Breast Cancer ...................................................................... 70  
1.3.1  Nonclinical Pharmacokinetics  ............................................................................... 70  
1.3.2  Nonclinical Safety  ................................................................................................. 70  
1.4 Rationale for the Study  .......................................................................................... 72  
1.5 Rationale for the Starting Dose  ............................................................................. 72  
1.5.1  Rationale for Recommended Phase 2 Dose .......................................................... 73  
1.6 Risk Assessment and Summary  ............................................................................ 73  
2. STUDY OBJECTIVES  ......................................................................................... 73  
2.1 Phas e 1 Primary Objective  .................................................................................... 73  
2.2 Phase 1 Secondary Objectives ............................................................................... 73  
2.3 Phase 1 Exploratory Objectives ............................................................................ 73  
2.4 Phase 2 Primary Objective .................................................................................... 74  
2.5 Phase 2 Secondary Objectives ............................................................................... 74  
2.6 Phase 2 Exploratory Objectives ............................................................................ 74  
3. STUDY SUBJECT POPULATION AND DISCONTINUATION  ...................... 74  
3.1 Inclusion Criteria  ................................................................................................... 75  
3.2 Exclusion Criteria  .................................................................................................. 77  
3.3 Discontinuation from Study Treatment ................................................................. 79  
4. STUDY REGISTRATION .................................................................................... 80 
5. STUDY DESIGN  .................................................................................................. 81  
5.1 Phase 1  ................................................................................................................... 82  
5.1.1  Starting Dose and Cohort Management ................................................................ 82  
5.1.2  Definition of Dose -Limiting Toxicities  ................................................................. 84  
5.1.3  Maximum Tolerated Dose  ..................................................................................... 86  
5.1.4  Recommended Phase 2 Dose ................................................................................ 86  
5.2 Phase 2  ................................................................................................................... 86  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 64 of 160 5.2.1  Food- Effect Evaluation  ......................................................................................... 87  
5.2.2  Endometrium Evaluation in Subjects .................................................................... 88  
5.3 Treatment Plan  ...................................................................................................... 89  
5.4 Concomitant Medications...................................................................................... 89 
5.4.1  Permitted Concomitant Medications  ..................................................................... 89  
5.4.2  Prohibited Concomitant Medications  .................................................................... 90  
6. DOSE MODIFICATIONS  .................................................................................... 91  
6.1 Dose Modifications Due to Toxicity ..................................................................... 91  
7. STUDY ASSESSMENTS AND EVALUATIONS  .............................................. 95  
7.1 Overview ............................................................................................................... 95  
7.2 Baseline Study Assessments (Visit 2)  ................................................................... 96  
7.3 Study Treatment Assessments  ............................................................................... 97  
7.3.1  Cycle 1 Days 1 (Visit 3), 8 (Visit 4), 15 (Visit 5), and 22 (Visit 6)  ...................... 97  
7.3.2  Cycle 2 Days 1 (Visit 7) and 15 (Visit 8) .............................................................. 98  
7.3.3  Cycle 3 Days 1 (Visit 9) and 15 (Visit 10) ............................................................ 99  
7.3.4  Cycle 4 and Beyond - Days 1 (Visits 11, 13, 15, and beyond) and 15 (Visit 
12) ........................................................................................................................ 100  
7.4 Response Assessment Every 8 Weeks ................................................................ 101  
7.5 End-of-Treatment Visit  ....................................................................................... 101  
7.6 Follow-up after End-of- Treatment Visit  ............................................................. 102  
7.7 Pharmacokinetics  ................................................................................................. 102  
7.8 Biomarkers  .......................................................................................................... 103  
7.8.1  Prescreening Phase .............................................................................................. 104  
7.8.2  Screening Phase Biomarkers  ............................................................................... 104  
7.8.3  Baseline and Treatment Phase Biomarkers  ......................................................... 105  
7.8.4  Pharmacogenetics Assessment  ............................................................................ 105  
7.9 Biomarkers of Bone Resorption and Formation  .................................................. 106  
8. DRUG FORMULATION, AVAILABILITY, ADMINISTRATION, AND TOXICITY INFORMATION  ............................................................................. 106
 
8.1 H3B-6545 ............................................................................................................ 106  
8.1.1  Labeling, Packaging, and Supply ........................................................................ 106  
8.1.2  Administration of H3B-6545............................................................................... 107  
8.1.3  Precautions and Risks Associated with H3B -6545 ............................................. 107  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 65 of 160 8.2 Storage Conditions .............................................................................................. 108  
8.3 Accountability for All Study Drugs .................................................................... 108  
9. RESPONSE EVALUATIONS AND MEASUREMENTS  ................................ 109  
10. STATISTICAL CONSIDERATIONS ................................................................ 109  
10.1  Statistical Design  ................................................................................................. 109  
10.2  Phase 1 Primary Objective .................................................................................. 110  
10.3  Phase 1 Secondary Objectives ............................................................................. 110  
10.4  Phase 1 Exploratory Objectives .......................................................................... 110  
10.5  Phase 2 Primary Objective .................................................................................. 110  
10.6  Phase 2 Secondary Objectives ............................................................................. 110  
10.7  Phase 2 Exploratory Objectives .......................................................................... 110  
10.8  Study Endpoints .................................................................................................. 111  
10.8.1.1  Phase 1  ................................................................................................................. 111  
10.8.1.2  Phase 2  ................................................................................................................. 112  
10.9  Sample Size Considerations ................................................................................ 112  
10.9.1  Sample Size Calculation for Phase 1  ................................................................... 112  
10.9.2  Sample Size Calculation for Phase 2  ................................................................... 112  
10.9.2.1  Sample Size Calculation for the Phase 2 Food- Effect Sub -Study  ....................... 113  
10.9.2.2  Sample Size Calculation for the Phase 2 Endometrium Sub-Study .................... 113  
10.10  Anal ysis Populations ........................................................................................... 114  
10.11  Data Analysis  ...................................................................................................... 114  
10.11.1  Subject Disposition  ............................................................................................. 115  
10.11.2  Demographic and Other Baseline Characteristics  ............................................... 115  
10.11.3  Prior and Concomitant Therapy .......................................................................... 115  
10.11.4  Efficacy Analysis  ................................................................................................ 115  
10.11.5  Safety Analysis  .................................................................................................... 116  
10.11.5.1  Extent of Exposure .............................................................................................. 117  
10.11.5.2  Adverse Events .................................................................................................... 117  
10.11.5.3  Laboratory Values  ............................................................................................... 118  
10.11.5.4  Vital Signs  ........................................................................................................... 119  
10.11.5.5  Electrocardiograms  .............................................................................................. 119  
10.11.6  Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and Other  
Biomarker Analyses  ............................................................................................ 119  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 66 of 160 10.11.6.1  Pharmacokinetic Analyses .................................................................................. 119  
10.11.6.2  Pharmacodynamic, Pharmacogenetic, and Other Biomarker Analyses .............. 120  
10.12  Analysis Time Points  .......................................................................................... 120  
10.12.1  Primary Analysis  ................................................................................................. 120  
10.12.2  Planned Interim Analysis  .................................................................................... 120  
10.12.3  Safety Review Committee ................................................................................... 120  
11. SAFETY REPORTING  ...................................................................................... 121  
11.1  Definitions  ........................................................................................................... 121  
11.1.1  Adverse Events  .................................................................................................... 121  
11.1.2  Serious Adverse Event  ........................................................................................ 123  
11.1.3  Adverse Reaction  ................................................................................................ 124  
11.1.4  Suspected Adverse Reaction  ............................................................................... 124  
11.1.5  Recording and Reporting of Adverse Events ...................................................... 124  
11.1.5.1  Regulatory Reporting of Adverse Events ............................................................ 125  
11.2  Serious Adverse Event Reporting by Investigators ............................................. 125  
11.2.1  Investigator Reporting After Study Discontinuation ........................................... 126  
11.3  Recording of Adverse Events and Serious Adverse Events ................................ 126  
11.3.1  Diagnosis Versus Signs and Symptoms  .............................................................. 126  
11.3.2  Persistent or Recurrent Adverse Events  .............................................................. 126  
11.3.3  Abnormal Laboratory Values .............................................................................. 126  
11.3.4  Deaths  .................................................................................................................. 127  
11.3.5  Hospitalization, Prolonged Hospitalization, or Surgery ...................................... 127  
11.3.6  Pre-Existing Medical Conditions ........................................................................ 127  
11.3.7  New Cancers........................................................................................................ 128 
11.3.8  Pregnancy, Abortion, Birth Defects/Congenital Anomalies  ............................... 128  
11.3.9  H3B-6545 Overdose ............................................................................................ 128  
11.4  Cardiovascular  ..................................................................................................... 129  
11.5  Sponsor Serious Adverse Event Reporting Requirements .................................. 129  
11.5.1.1  Expedited Reporting ............................................................................................ 130  
12. QUALITY ASSURANCE AND QUALITY CONTROL  .................................. 130  
12.1  Monitoring ........................................................................................................... 130  
12.2  Audits and Inspections ........................................................................................ 130  
13. ETHICAL, FINANCIAL, AND REGULATORY CONSIDERATIONS  .......... 130  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 67 of 160 13.1  Institutional Review Board Approval.................................................................. 130  
13.2  Regulatory Approval  ........................................................................................... 131  
13.3  Informed Consent ................................................................................................ 131  
13.3.1  Confidentiality  ..................................................................................................... 131  
13.3.1.1  Subject Confidentiality  ........................................................................................ 131  
13.3.1.2  Investigator and Staff Information  ...................................................................... 132  
13.4  Financial Information  .......................................................................................... 132  
14. RESEARCH RETENTION AND DOCUMENTATION OF THE STUDY  ...... 133  
14.1  Amendments to the Protocol ............................................................................... 133  
14.2  Documentation Required to Initiate the Study .................................................... 133  
14.3  Study Documentation and Storage ...................................................................... 134  
14.4  Data Collection  .................................................................................................... 135  
14.5  Discontinuation of Study ..................................................................................... 136  
14.6  Disclosure and Publication Policy ....................................................................... 136  
15. REFERENCES .................................................................................................... 137  
16. APPENDICES ..................................................................................................... 142  
 
  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 68 of 160 LIST OF TABLES  
Table 1  Dose Cohorts in H3B-6545 Dose Escalation Phase  ............................. 83  
Table 2  Definition of Dose -Limiting Toxicity (Cycle 1 Phase 1 Only) or 
Dose -Modifying Event (Cycle 2 or Beyond and Any Cycle in 
Phase  2) ................................................................................................... 85  
Table 3  Dose Modifications Due to Hematologic Toxicities  ............................. 92  
Table 4  Dose Modification for Grade 3, Grade 4, or Intolerable Grade 2 
Non-Hematologic Toxicities  .................................................................. 93  
Table 5   Time Points and Minimum Blood Volume for Biomarker 
Specimensg ............................................................................................ 104  
 
LIST OF FIGURES  
Figure 1:  Study Design ........................................................................................... 81  
 
LIST OF APPENDICES  
APPENDIX A:  ECOG Performance Status Criteria  ....................................................... 143  
APPENDIX B:  New York Heart Association (NYHA) Classification of Cardiac 
Disease  ................................................................................................... 144  
APPENDIX C:  Guidelines for Women of Childbearing Potential ................................. 145  
APPENDIX D:  Prescreening for ESR1 Mutations (Amendment 6 and subsequent 
amendments) .......................................................................................... 147  
APPENDIX E:  Schedule of Assessments  ....................................................................... 148  
APPENDIX F:  Extension Phase ..................................................................................... 153  
APPENDIX G:  Response Evaluation Criteria in Solid Tumors (RECIST) Version  1.1 . 155  
APPENDIX H:  Conc omitant Medications ...................................................................... 156  
APPENDIX I:  Drugs That Prolong Qt Interval And/Or Induce Torsades De Pointes .. 158  
APPENDIX J:  Security of the Samples, Use of the Samples, and Retention of the 
Samples  .................................................................................................. 160  
 
 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 69 of 160 1. INTRODUCTION  
1.1 Background 
In 2015, an estimated 231,840 new cases of invasive breast cancer were diagnosed in women in 
the United States (US), as well as an estimated 60,290 additional cases of in situ breast cancer.  It was estimated that over 3 million women in the US are living with breast cancer (NCI SEER , 
2016) .  The estimated number of deaths from breast cancer in the same year in the US was 
40,290 ( American Cancer Socie ty, 2015) .  In the European Union, the predicted number of 
deaths from breast cancer among women for 2016 was 92,300 ( Malvezzi et al. , 2016 ).   
The age- standardized incidence rate of breast cancer is 92.9 cases per 100,000   person- years in 
the US 95.0 cases per 100,000 person-years in the United Kingdom [UK] and 51.5 cases per 100,000 person- years in Japan and the incidence is increasing with time ( Ferlay et al. , 2013) .   
1.2 Role of the Estrogen Pathway in Breast Cancer 
Approximately 70% of breast cancers expr ess estrogen receptor alpha (ER α), a hormone-
regulated transcription factor (Lumachi et al. , 2013).   Nonclinical and clinical epidemiological 
studies highlight an important oncogenic role for estrogen and ER α, through genomic- and non-
genomic- mediated acti vation of proliferation and survival pathways, in the genesis and 
progression of breast cancer ( Spicer and Pike , 1993).  Mouse models genetically engineered to 
express ER α induce mammary adenocarcinoma formation ( Tilli et al. , 2003), whereas small 
inhibitor ribonucleic acid -mediated knockdown of ERα results in reduced proliferation and 
enhanced apoptosis in vitro and in vivo ( Fu et al. , 2006) , confirming the critical role for this 
pathway in breast cancer.   
Several estrogen receptor (ER) -directed therapies have been developed to antagonize the 
oncogenic ER α function in pre - and post-
menopausal women with locally advanced, recurrent, 
or metastatic cancer, including selective ER modulators such as tamoxifen, selective ER downregulators such as fulvestrant, selective nonsteroidal aromatase inhibitors such as 
anastrozole and letrozole, and steroidal aromatase inhibitors such as exemestane ( Beslija et al. , 
2009).  Although these therapies have demonstrated efficacy in the nonclinical and clinical settings, innate and acquired resistance remains a major challenge.   
Several mechanisms of resistance to ER α antagonists have been identified including: 
ERα/human epidermal growth factor re
ceptor- 2 (HER2) “crosstalk” ( Shou et al., 2004), aberrant 
expression of ERα coactivators/corepressors ( Osborne et al. , 2003) and most recently, recurrent 
mutations in ER α (Li et al. , 2013;  Robinson et al., 2013; Toy et al., 2013 ).  The recurrent 
mutations in ER α, which are enriched in nearly 30% of endocrine- therapy resis tant metastases, 
confer ligand -independent activation of the ERα pathway ( Li et al. , 2013; Robinson et al., 2013; 
Toy et al., 2013; Merenbakh- Lamin et al. , 2013 ; Yu et al., 2014;  Segal and Dowsett, 2014; 
Jeselsohn et al. , 2014; Chandarlapaty et al., 2016), and are associated with more aggressive 
disease biology with shorter overall survival (OS) relative to WT ER α (Chandarlapaty et al., 
2016).  Furthermore, ERα mutations (ER αmut) confer partial resistance to existing classes of 
endocrine therapies, likely through promoting constitutive activity.   
The fact that current endocrine therapies are only partially effective in the ER αmut setting and 
that a significant proportion of endocrine -therapy resistant metastases continue to remain 
 
CO N FI D E N TI A L  
ST U D Y D R U G :  H 3 B -6 5 4 5  
PR O T O C O L AM E N D M E N T 9:   2 9  AU G 2 0 2 2  P a g e 7 0  of 1 6 0  d e p e n d e nt o n E R α si g n ali n g f or gr o wt h a n d s ur vi v al i n di c at e s a c o nti n ui n g n e e d t o d e v el o p t h e 
n e xt g e n er ati o n of E R α a nt a g o ni st s t h at c a n o v er c o m e a b err a nt a cti viti e s of b ot h wil d -t y p e 
( E R αW T ) a n d m ut a n t E R α.  T o t hi s e n d, w e i ntr o d u c e h er ei n a n or all y bi o a v ail a bl e s m all 
m ol e c ul e i n hi bit or t h at p ot e ntl y i n hi bit s b ot h E R αW T  a n d E R α m ut  f u n cti o n b y a n o v el m o d e of 
a cti o n.  
1. 3  R ol e of H 3 B - 6 5 4 5 i n B r e a st C a n c e r 
H 3 B - 6 5 4 5 i s a n or al, s el e cti v e, a n d c o v al e nt s m all- m ol e c ul e i n hi bit or of E R.  H 3 B - 6 5 4 5 bi n d s 
p ot e ntl y t o E R α ( h alf - m a xi m al e x hi bit or y c o n c e ntr ati o n [ E C 5 0 ],  a n d E R β ( E C 5 0 , 
 a n d i s a p ot e nt i n hi bit or of E R α c o a cti v at or r e cr uit m e nt ( h alf -m a xi m al i n hi bit or y 
c o n c e ntr ati o n [I C 5 0 ],  d e m o n str ati n g  - f ol d s el e cti vit y o v er ot h er n u cl e ar 
h or m o n e r e c e pt or s t e st e d.  A d diti o n of H 3 B- 6 5 4 5 t o E R α W T  a n d E R α m ut  br e a st c a n c er c ell li n e s 
l e a d s t o d o s e - d e p e n d e nt i n hi biti o n of E R α- d e p e n d e nt tr a n s cri pti o n a n d c o n c o mit a nt r e d u cti o n i n 
c ell pr olif er ati o n.  Or al d o si n g of H 3 B - 6 5 4 5 i n mi c e l e a d s t o i n hi biti o n of E R α- d e p e n d e nt 
tr a n s cri pti o n i n t h e E R αm ut  e x pr e s si n g s u bj e ct- d eri v e d x e n o gr aft m o d el.  H 3 B- 6 5 4 5 al s o l e a d s t o 
d o s e- d e p e n d e nt t u m or gr o wt h i n hi biti o n a n d/ or st a si s i n b ot h E R α W T  a n d E R αm ut  x e n o gr aft 
m o d el s at w ell -t ol er at e d d o s e s.  
T h e s e n o n cli ni c al fi n di n g s s u p p ort t h e cli ni c al i n v e sti g ati o n of H 3 B- 6 5 4 5 i n s u bj e ct s wit h E R- 
p o siti v e ( E R αW T  a n d E R α m ut ) H E R 2 -n e g ati v e br e a st c a n c er.   
1. 3. 1  N o n cli ni c al P h a r m a c o ki n eti c s  
T h e p h ar m a c o ki n eti c s ( P K ) of H 3 B- 6 5 4 5 h a v e b e e n c h ar a ct eri z e d i n S pr a g u e D a wl e y r at s a n d 
c y n o m ol g u s m o n k e y s, s p e ci e s u s e d i n t h e n o n cli ni c al s af et y e v al u ati o n of H 3 B- 6 5 4 5.  T h e P K of 
H 3 B -6 5 4 5 w er e c h ar a ct eri z e d b y a l o w cl e ar a n c e i n r at s a n d a m o d er at e cl e ar a n c e i n m o n k e y s 
aft er i ntr a v e n o u s a d mi ni str ati o n, wit h t er mi n al eli mi n ati o n h alf -lif e (t ½) of   h o ur s i n r at s a n d 
 h o ur s i n m o n k e y s.  R e n al cl e ar a n c e w a s n ot a si g nifi c a nt c o ntri b ut or t o t h e eli mi n ati o n of 
H 3 B - 6 5 4 5 i n r at s.   
I n b ot h s p e ci e s, H 3 B- 6 5 4 5 a p p e ar s t o b e di stri b ut e d w ell i nt o ti s s u e s wit h a v ol u m e of 
di stri b uti o n at st e a d y st at e t h at e x c e e d s t ot al b o d y w at er.  I n b ot h s p e ci e s, aft er or al d o si n g, t m a x  
w a s t y pi c all y b ei n g a c hi e v e d at   h o ur s p o st d o s e a n d H 3 B- 6 5 4 5 or al bi o a v ail a bilit y w a s 
m o d er at e.  I n vitr o, H 3 B- 6 5 4 5 s h o w e d si mil ar hi g h pl a s m a pr ot ei n bi n di n g i n r at s, m o n k e y s, a n d 
h u m a n s  a n d w a s pr e d o mi n a ntl y m et a b oli z e d b y h u m a n c yt o c hr o m e P 4 5 0 
( C Y P) 3 A 4, f oll o w e d b y C Y P 3 A 5 a n d C Y P 2 C 8. H 3 B- 6 5 4 5 i s a s u b str at e of P- gl y c o pr ot ei n ( P- 
g p), b ut n ot t h e br e a st c a n c er r e si st a n c e pr ot ei n ( B C R P).  
1. 3. 2  N o n cli ni c al S af et y  
T h e t o xi c ol o g y pr o gr a m f or H 3 B- 6 5 4 5 w a s d e si g n e d t o s u p p ort t h e or al ( P O) a d mi ni str ati o n of 
H 3 B - 6 5 4 5 a s a si n gl e a g e nt gi v e n o n c e d ail y ( Q D) f or at l e a st 2 8 d a y s t o w o m e n wit h m et a st ati c 
br e a st c a n c er.  T h e h y dr o c hl ori d e s alt f or m of H 3 B- 6 5 4 5 w a s u s e d i n all pi v ot al s af et y st u di e s 
a n d i s i nt e n d e d f or cli ni c al u s e i n P h a s e  1/ 2 tri al s.   
R at s a n d c y n o m ol g u s m o n k e y s w er e c h o s e n a s a p pr o pri at e s p e ci e s f or t o xi c ol o g y st u di e s b a s e d 
o n m et a b oli c pr ofil e s si mil ar t o t h at of h u m a n s, a n d o nl y f e m al e a ni m al s w er e u s e d i n t o xi c ol o g y 
st u di e s b a s e d o n t h e i nt e n d e d s u bj e ct p o p ul ati o n.   
T h e n o n cli ni c al t o xi cit y fi n di n g s i n t h e t o xi c ol o g y st u di e s i n cl u d e d a nti ci p at e d p h ar m a c ol o gi c al 
eff e ct s of E R i n hi biti o n, l y m p h o c yt e d e pl eti o n i n p eri p h er al l y m p h oi d or g a n s, g a str oi nt e sti n al C CI 
C CI 
C CI C CI 
C CI 
C CI 
C
C
C CI 
 
CO N FI D E N TI A L  
ST U D Y D R U G :  H 3 B -6 5 4 5  
PR O T O C O L AM E N D M E N T 9:   2 9  AU G 2 0 2 2  P a g e 7 4  of 1 6 0  2. 4  P h a s e 2 P ri m a r y O bj e cti v e 
T h e pri m ar y o bj e cti v e of t h e P h a s e 2 p orti o n of t hi s st u d y i s t o: 
● E sti m at e t h e effi c a c y of H 3 B - 6 5 4 5 i n t er m s of b e st o v er all r e s p o n s e r at e, D o R, D C R, 
cli ni c al b e n efit r at e ( C B R), P F S, a n d O S i n all s u bj e ct s wit h ( E R) - p o siti v e, H E R 2- 
n e g ati v e br e a st c a n c er a n d t h o s e wit h a n d wit h o ut E R α m ut ati o n (i n cl u di n g a cl o n al E S R 1 
Y 5 3 7 S m ut ati o n). 
2. 5  P h a s e 2 S e c o n d a r y O bj e cti v e s  
T h e s e c o n d ar y o bj e cti v e s of t h e P h a s e 2 p orti o n of t hi s st u d y ar e t o:  
● F urt h er c h ar a ct eri z e t h e s af et y of H 3 B - 6 5 4 5 i n t hi s s u bj e ct p o p ul ati o n. 
● F urt h er c h ar a ct eri z e t h e P K of H 3 B -6 5 4 5. At l e a st s p ar s e P K s a m pl e s will b e c oll e ct e d 
fr o m all s u bj e ct s o n st u d y . 
● E v al u at e t h e eff e ct of a hi g h -f at m e al o n t h e r el ati v e bi o a v ail a bilit y of H 3 B - 6 5 4 5. 
● A s s e s s t h e eff e ct of H 3 B - 6 5 4 5 o n s er u m b o n e t ur n- o v er m ar k er s, n a m el y b o n e- s p e cifi c 
al k ali n e p h o s p h at a s e ( B S A P, f or o st e o cl a st m et a b oli s m), a mi n o- t er mi n al pr o p e pti d e of 
t y p e 1 c oll a g e n ( PI N P, f or b o n e f or m ati o n), a n d C- t er mi n al cr o s s -li n ki n g t el o p e pti d e of 
t y p e 1 c oll a g e n ( C T X, f or b o n e r e s or pti o n). 
● A s s e s s t h e eff e ct of H 3 B - 6 5 4 5 o n e n d o m etri al t hi c k n e s s a n d ut eri n e v ol u m e.  T hi s 
o bj e cti v e will b e a s s e s s e d i n a s u b gr o u p of w o m e n wit h i nt a ct ut eri.  
2. 6  P h a s e 2 E x pl o r at o r y O b j e cti v e s  
T h e e x pl or at or y o bj e cti v e s of t h e P h a s e 2 p orti o n of t hi s st u d y ar e t o: 
3.  S T U D Y S U B J E C T P O P U L A T I O N A N D D I S C O N T I N U A T I O N  
T h e st u d y will i n cl u d e w o m e n wit h E R- p o siti v e, H E R 2 -n e g ati v e, l o c all y a d v a n c e d or m et a st ati c 
br e a st c a n c er.  I n A m e n d m e nt 6 ( a n d s u b s e q u e nt a m e n d m e nt s), p ot e nti al s u bj e ct s will si g n a 
pr e s cr e e ni n g c o n s e nt t o pr o vi d e a w h ol e bl o o d s a m pl e t o p erf or m E S R 1  m ut ati o n a n al y si s. 
Eli gi bl e s u bj e ct s m u st h a v e E S R 1 Y 5 3 7 S m ut ati o n at all eli c fr e q u e n c y ( A F) ≥ 0. 5 %, i n t h e C CI 
C CI 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 75 of 160 absence of D538G mutation at the same AF value.  This will be determined by central laboratory 
assess ment prior to signing the main study consent, unless prior authorization has been received 
by the Sponsor, based on local mutation analysis. 
Eligible subjects must have progressed on their most recent therapy.  The investigator or 
designee must ensure that  only subjects who meet all the following inclusion criteria and none of 
the exclusion criteria are enrolled in the study. 
3.1 Inclusion Criteria  
Subjects must meet the following criteria in order to be included in the research study: 1. Prescreening:  Subjects must have clonal ESR1 Y537S mutation at AF ≥0.5%, in the absence 
of ESR1 D538G at AF ≥0.5%, as determined at prescreening by a Sponsor- designated central 
laboratory from a Nucleic Acids Whole Blood ( plasma cfDNA ) sample.  
2. Subject has signed informed consent form (ICF) before any trial -related activities and 
according to local guidelines.  Main ICF may only be signed once positive mutation status is 
confirmed by a sponsor-designated central laboratory, unless prior authoriza tion has been 
received by the Sponsor, based on local mutation analysis.   
3. Only females are eligible.  Menopausal status:  
 − Postmenopausal defined by:  
 
a) Prior bilateral oophorectomy,  
b) Age ≥60 years, or  
c) Age <60 years and amenorrhea for 12 or more months (in the absence of chemothera
py, tamoxifen, toremifene, or ovarian suppression); or a follicle -
stimulating hormone value >40 mIU/mL and an estradiol value <40  pg/mL 
(140 pmol/L) or in postmenopausal ranges per local reference ranges 
Or  
− Premenopausa
l or perimenopausal concurrently given a luteinizing hormone- releasing 
hormone (LHRH) agonist starting at least 4 weeks before the start of trial therapy and is 
planned to continue LHRH  during the study.    
4. Subject has a histologically and/or cytologically confirmed diagnosis of ER- positive breast 
cancer by local laboratory.  
5. Subject has HER2- negative breast cancer as defined by American Society for Clinical 
Oncology-College of American Pathologists guideline s (Wolff et al. , 2013) .   
6. Subject must have progressed on the most recent therapy.   
7. Prior therapy for breast cancer in the advanced/metastatic setting must have included a 
minimum of: 
a) two prior hormonal therapies, or  
b) one prior hormonal therapy and one prior chemotherapy regimen, or  
c) one prior hormonal therapy and a CDK4/6 inhibitor.   
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 76 of 160 Note: Subjects may have received treatment for brain metastases, but must be neurologically 
stable, completed radiotherapy and off corticosteroids for at least one month prior to starting trial therapy.  
Note:  Subjects enrolled under Amendment 6 ( and subs equent amendments) must have 
received prior therapy including at least one prior hormonal therapy and a CDK4/6 inhibitor. Up to one prior chemotherapy in the metastatic setting is allowed.  
8. Subject must have at least one biopsiable lesion in the Phase 1 portion. In the Phase 2 part of the trial subjects must also have either:  
a) at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, or  
b) at least one predominantly lytic bone lesion.   
Note:  Subjects enrolled under Amendment 6 ( and subsequent amendments) must have at 
least one measurable le sion as per RECIST 1.1. 
9. Subject must be willing to undergo tumor biopsies prior to treatment and on Cycle 2 Day 1.  
In the Phase 2 part of the trial, subjects with bone-only disease, or subjects for whom a biopsy is contra-indicated, may opt out of providing tumor biopsies following investigator concern and direct discussion and approval from the Sponsor.   
Note: A subset of subjects in Phase 2 will be required to provide tumor tissue until tumor 
pairs have been collected from at least 15 subjects with ERα
WT and 15 subjects with ERαmut 
(determined retrospectively by Sponsor- designated central laboratory test).  
Note:  For subjects enrolled under Amendment 6 (and subsequent amendments), a recent archival tumor tissue obtained within the 6 months prior to enrollment or a fresh tumor 
biopsy must be provided. A second biopsy after initiating trial therapy is not required. 
10. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. 
11. Subject has adequate bone marrow and organ function, as defined by the following laboratory values: 
− Absolute neutrophil count ≥1.5 × 10
9/L 
− Platelets ≥100 × 109/L 
− Hemoglobin ≥9.0 g/dL (may have been transfused). 
− Potassium, sodium, calcium (corrected for serum albumin) and magnesium <National 
Cancer Inst itute Common Terminology Criteria for Adverse Events (NCI CTCAE) 
Grade 2  
−  Cockcroft- Gault based creatinine clearance ≥35 mL/min  
− Serum albumin ≥3.0 g/dL (≥30 g/L)  
− In the absence of liver metastases, AST, and ALT should be below 3.0 × upper limit of normal (ULN).  If the subject has liver metastases, ALT and AST should be below 5.0 × ULN.  
− Total serum bilirubin <ULN. For subjects with documented Gilbert’s syndrome, t otal 
serum bilirubin <2.5 × ULN 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 77 of 160 12. Age ≥18 years 
13. Willingness and ability to comply with study and follow-up procedures 
14. Ability to understand the nature of this study and give written informed consent 
3.2 Exclusion Criteria  
Subjects who meet any of the following criteria will be excluded from study entry:  
1. Subject with bone-only disease (Phase 1 only).   
2. Phase 2 subjects may have predominantly lytic bone only disease.  
Note:  Subjects enrolled under Amendment 6 ( and subsequent amendments) must have at 
least one measurable lesion as per RECIST 1.1.  
3. Subject with inflammatory breast cancer.  
4. Subject has received more than one prior chemotherapy regimen for metastatic disease 
(Phase 2 only). 
5. Subject has had prior antineoplastic therapy within 14 days prior to starting study drug.   
6. Subject is currently receiving or has received systemic corticosteroids ≤2 weeks prior to starting study drug, or has not fully recovered from side effects of such treatment.  
Note: The following uses of corticosteroids are permitted: single doses, topical applications 
(eg, for rash), inhaled sprays (eg , for obstructive airways diseases), eye drops or local 
injections (eg , intra -articular).  
7. Subject has received radiotherapy ≤4 weeks or limited field radiation for palliation ≤2 weeks prior to starting study drug, and who has not recovered to Grade 1 or better from related side effects of such therapy (with the exception of alopecia) and/or for whom ≥30% of the bone marrow was irradiated.  
8. Major surgical procedures ≤14 days of beginning study drug, or minor surgical procedures ≤7 days, or has not recovered from major side effects.  No waiting required following port-a-cath placement.
   
9. Subject has active cardiac disease or a history of cardiac dysfunction, including any of the following:  
− History of angina pectoris, symptomatic pericarditis, or myocardial infarction within 12 months prior to study entry  
− History of documented congestive heart failure (New York Heart Association functional classification III or IV)  
− Documented cardiomyopathy 
− Subject has a left ventricular ejection fraction <50% as determined by multiple -gated 
acquisition (MUGA) scan or echocardiogram 
− History of any cardiac arrhythmias, eg, ventricular, supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months 
− A prolonged QT interval corrected for HR using Fridericia’s formula (QTcF) >450  msec 
as demonstrated by a repeated ECG; a history of risk factors for Torsade de pointes (eg, 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 78 of 160 heart  failure, hypokalemia, and family history of long QT syndrome); or the use of 
concomitant medications that prolonged the QTcF interval 
− Subject has a resting pulse rate <60 bpm. 
10. Subject has impairment of GI function or GI disease that may significantly alter the 
absorption of H3B-6545 (eg, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).  
11. Subject has a known hypersensitivity to any of the excipients of H3B-6545. 
12. Subject has a known history of human immunodeficiency virus infection or hepatitis C virus, or requires treatment with protease inhibitors (testing not mandatory).  
13. Subject has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, con traindicate subject participation in the clinical study (eg , 
chronic pancreatitis, active hepatitis, etc).  
14. Subject that received in the 7 days prior to the administration of study drug or is currently receiving any of the following medications (see Appendix H and Appendix I  for details):  
a. Known strong inducers or inhibitors of CYP3A4 or P-gp  
b. Medications that have a known risk to prolong the QT interval or induce Torsades de Pointes  
c. Medications that have a narrow therapeutic window and are predominantly metabolized through CYP2C8, CYP2C9, CYP2C19, or CYP3A4.  
d. Medications that have a narrow the rapeutic window and are BCRP substrates.  
e. Herbal preparations/medications.  These herbal medications include, but are not limited to, St. John’s wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.   
15. Any adverse event related to previous therapies for breast cancer that has not resolved to ≤Grade 1.  
16. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß- hCG] (or human chorionic gonadotropin 
[hCG]) test with a minimum sensitivity of 25 IU/L or equivalent units of ß -hCG [or hCG]).  
A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. 
17. Females of childbearing potential who: 
● Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double- barrie r method [such as condom plus diaphragm with 
spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period or for 28 days after study drug discontinuation. 
● Are cur rently abstinent, and do not agree to use a double- barrier method (as described 
above) or refrain from sexual activity during the study period or for 28 days after study drug discontinuation. 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 79 of 160 ● Are using hormonal contraceptives but are not on a stable dose o f the same hormonal 
contraceptive product for at least 4 weeks before dosing and who do not agree to use the 
same contraceptive during the study or for 28 days after study drug discontinuation. 
All females will be considered to be of childbearing potential unless they are postmenopausal 
[amenorrheic for at least 12  consecutive months, in the appropriate age group, and without 
other known or suspected cause] or have been sterilized surgically [ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1  month before 
dosing]). 
18. Alcohol dependency within 6 months before study entry.  
19. Subject has a concurrent malignancy or malignancy within 3 years of enrollment, with the exception of adequately tr eated basal or squamous cell carcinoma, non -melanomatous skin 
cancer, or curatively resected cervical cancer.  
20. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
  
21. Subjects with advanced, symptomatic visceral spread, that are at risk of life- threatening 
complications in the short term.  
22. Subjects with abnormal coagulation profiles, or any history of coagulopathy within 6 months prior to the first dose of study drug, including history of deep vein thrombosis (DVT) or pulmonary embolism.  
Note: subjects (except pre/perimenopausal women) with  adequately treated catheter -related 
venous thrombosis occurring more than one month prior to the first dose of study drug will be allowed to participate. 
23. Prothrombin time/international normalized ratio (INR) >1.5 times the upper limit of normal (ULN) or o utside therapeutic range if receiving anticoagulation that would affect 
the prothrombin time/INR.  
Note: subjects (except pre/perimenopausal women) treated with an anticoagulant, that affects prothrombin time/INR, for a stable and allowed medical condition  (eg, well 
controlled atrial fibrillation), will be allowed to participate, provided dose and coagulation parameters (as defined by local standard of care) are stable for at least one month prior to the first dose of study drug (hospital data prior to date  of signature of the ICF will be used if 
necessary).  
3.3 Discontinuation from Study Treatment  
Subjects will be discontinued from study treatment for any of the following reasons: 
● Disease progression  
● Irreversible or intolerable toxicity or abnormal laboratory values thought to be related to 
drug toxicity 
● Cycle 1 DLT  
● Conditions requiring therapeutic intervention not permitted by the protocol 
● Intercurrent illness (at the investigator’s discretion  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 80 of 160 ● Inability of the subject to comply with study requirements, or subject is lost to follow -up 
● Subject requests to discontinue treatment  
● Subject withdraws consent from the study  
● Pregnancy 
After discontinuation from protocol treatment, subjects must be followed for adverse events 
(AEs) for 28 days after t heir last dose of study drug.  All new AEs, including serious AEs 
(SAEs), occurring during this period must be reported and all SAEs must be followed until resolution, unless, in the opinion of the investigator, these events are not likely to improve becau se of the underlying disease.  In this case, the investigator must record his or her reasoning 
for this decision in the subject’s medical records and indicate on the AE pages that the outcome is not resolved on the Electronic Case Report Form (eCRF).  
All s ubjects who have Grade 3 or 4 laboratory abnormalities (per NCI CTCAE v4.03) at the time 
of discontinuation must be followed until the laboratory values have returned to Grade 1,2 or baseline for the subject, unless it is, in the opinion of the investigator, not likely that these values are to improve.  In this case, the investigator must record his or her reasoning for making this decision in the subject’s medical records and indicate on the AE pages that the outcome is not resolved on the eCRF. 
4. STUDY REGISTRATION 
The subject must willingly consent after being informed of the procedures to be followed, the 
experimental nature of the treatment, and the potential benefits, alternatives, side effects, risks, and discomforts.  Human protection committee (Institutional Review Board [IRB]/Ethics Committee [EC]) approval of this protocol and consent form is required.  Eligible subjects who wish to participate in the study will be enrolled into the study. 
In Phase 1 of the study, the Sponsor or designee will notify sites via e- mail when a new Dose 
Level/Cohort is opened and enrollment slot(s) becomes available.  As soon as a potential subject 
has been identified following the slot availability announcement, sites will notify the Sponsor or 
designee via email.  Sponsor or designee will reply to verify an available slot, and reserve the 
slot for the subject.  Upon receipt of confirmation, sites will have 5 business days to consent the identified subject.  If a subject is not consented within 5 business days, the slot will open to all sites for enrollment.   
Sponsor or designee will also communicate to all sites via e -mail when a cohort has been fully 
reserved and screening is closed.  This communication may also include language that describes any opportunity for additional screening should a subject screen -fail and/or meet replacement 
criteria.  
Once a site receives confirmation of successful slot reservation, the subject may be consented and screening procedures may begin.  All screening procedures must be completed as outlined in the protocol, and the Principal Investigator (PI ) must assess and confirm eligibility of the subject 
prior to requesting enrollment. Once eligibility is confirmed by the PI and Sponsor or designee, subject registration and dose level assignment will be performed by the Sponsor or designee.  
The Sponsor or designee will document the subject identification number, dose level, and date of 
 
CO N FI D E N TI A L  
ST U D Y D R U G :  H 3 B -6 5 4 5  
PR O T O C O L AM E N D M E N T 9:   2 9  AU G 2 0 2 2  P a g e 8 9  of 1 6 0  N o i nt er v e nti o n s will b e p erf or m e d o n a n y a s y m pt o m ati c ut eri n e a b n or m aliti e s t h at ar e  d et e ct e d 
at b a s eli n e.  A si mil ar a p pr o a c h w a s a d o pt e d f or t h e a s s e s s m e nt of t h e eff e ct of f ul v e str a nt o n t h e 
e n d o m etri u m ( M or al e s et al. , 2 0 0 9) . 
5. 3  T r e at m e nt Pl a n  
H 3 B- 6 5 4 5  O r al ( P O) c o nti n u o u s d ail y d o si n g  
T h e R P 2 D  w a s d et er mi n e d t o b e   ( s e cti o n 1. 5. 1  R ati o n al e f or R e c o m m e n d e d P h a s e 2 
D o s e ).  
All s u bj e ct s e nt eri n g t hi s st u d y will r e c ei v e H 3 B - 6 5 4 5 P O Q D  b a s e d o n d at a e v al u ati o n fr o m t h e 
pri or c o h ort( s).  Wit h t h e e x c e pti o n of t h e f e d d o s e s of t h e f o o d- eff e ct c o h ort ( eit h er C y cl e 1 D a y 
1 5 or C y cl e 1 D a y 2 2), s u bj e ct s will b e i n str u ct e d t o t a k e t h e d o s e o n a n e m pt y st o m a c h ( n o f o o d 
2 h o ur s b ef or e or 2 h o ur s aft er d o s e) at a p pr o xi m at el y t h e s a m e ti m e e a c h m or ni n g.  C a p s ul e s 
s h o ul d b e s w all o w e d w h ol e.  If t h e s u bj e ct mi s s e s a d o s e of st u d y dr u g b y l e s s t h a n 8 h o ur s, t h e 
s u bj e ct s h o ul d t a k e t h e d o s e a s s o o n a s p o s si bl e.  If a d o s e i s mi s s e d b y gr e at er t h a n 8 h o ur s, t h e 
s u bj e ct s h o ul d s ki p t h e mi s s e d d o s e a n d t a k e t h e n e xt d o s e a s s c h e d ul e d.  
F or A m e n d m e nt 6 a n d s u b s e q u e nt a m e n d m e nt s, s u bj e ct s m a y t a k e t h eir d o s e of H 3 B- 6 5 4 5 
irr e s p e cti v e of f o o d c o n diti o n s; u n d er f a sti n g or aft er a m e al.  
If v o miti n g o c c ur s aft er t a ki n g t h e st u d y m e di c ati o n, t h e s u bj e ct s h o ul d b e i n str u ct e d n ot t o 
r et a k e t h e d o s e.  S u bj e ct s s h o ul d t a k e t h e n e xt s c h e d ul e d d o s e of H 3 B- 6 5 4 5.  If v o miti n g 
p er si st s, t h e s u bj e ct s h o ul d c o nt a ct t h e i n v e sti g at or.  
N o r o uti n e pr o p h yl a cti c a nti e m eti c s will b e  gi v e n.  H o w e v er, t h e u s e of p al o n o s etr o n, 
pr o c hl or p er a zi n e, pr o m et h a zi n e, a n d c y cli zi n e f or m a n a g e m e nt of n a u s e a a n d v o miti n g i s 
all o w e d.  T h e u s e of o n d a n s etr o n a n d gr a ni s etr o n i s n ot p er mitt e d b e c a u s e of t h eir p ot e nti al t o 
pr ol o n g Q T i nt er v al. 
Tr e at m e nt  D ur ati o n 
T h e Pri m ar y C o m pl eti o n D at e f or t h e st u d y i s d efi n e d a s t h e d at e of t h e l a st vi sit f or a s s e s s m e nt 
of t h e pri m ar y e n d p oi nt of t h e l a st s u bj e ct o n t h e tri al.  
S u bj e ct s will b e e v al u at e d f or t o xi cit y at t h e st art of e a c h c y cl e ( 2 8 c al e n d ar d a y s).  E v er y 2 
c y cl e s, a d et ail e d a s s e s s m e nt will o c c ur wit h i m a gi n g, l a b or at or y c h e mi stri e s, a n d t u m or m ar k er s 
a s d efi n e d i n A p p e n di x E .  S u bj e ct s will c o nti n u e o n tr e at m e nt u ntil pr o gr e s si o n, a s d efi n e d i n 
A p p e n di x G  or  i nt ol er a n c e t o si d e eff e ct s, or wit h dr a w al of c o n s e nt.  
5. 4  C o n c o mit a nt M e di c ati o n s  
S u bj e ct s will b e i n str u ct e d n ot t o t a k e a n y a d diti o n al m e di c ati o n s d uri n g t h e c o ur s e of t h e st u d y 
wit h o ut pri or c o n s ult ati o n wit h t h e r e s e ar c h t e a m.  At e a c h vi sit, t h e s u bj e ct w ill b e a s k e d a b o ut 
a n y n e w m e di c ati o n s s h e i s t a ki n g or h a s t a k e n aft er t h e st art of t h e st u d y dr u g.   
5. 4. 1  P e r mitt e d C o n c o mit a nt M e di c ati o n s  
T h e u s e of p al o n o s etr o n, pr o c hl or p er a zi n e, pr o m et h a zi n e, a n d c y cli zi n e f or m a n a g e m e nt of 
n a u s e a a n d v o miti n g i s all o w e d.   T h e u s e of o n d a n s etr o n a n d gr a ni s etr o n i s n ot p er mitt e d 
b e c a u s e of t h eir p ot e nti al t o pr ol o n g Q T i nt er v al.  
U s e of a nt a ci d s i s all o w e d . C CI 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 90 of 160 Medications may be administered for maintenance of existing conditions prior to study 
enrollment or for a new condition  that develops while on study, including but not limited to the 
following:  
● Growth Factors:  Subjects receiving recombinant erythropoietin or darbepoietin -α prior to 
study start may continue to receive pretreatment doses.  
Following initiation of study treatment, the use of erythropoietic and granulocyte growth factors in accordan ce with local practice or American Society of Clinical Oncology 
guidelines may be implemented at the discretion of the treating physician.   
● Bisphosphonate use, as recommended according to practice guidelines as long as the subject has been on a stable dos e for >30 days prior to study enrollment   
● Receptor activator of nuclear factor kappa -B ligand inhibitor use, as recommended 
according to practice guidelines, as long as the subject has been on a stable dose >30 days prior to study enrollment  
● Anticoagulation with warfarin and derivatives will not be permitted.  However, a maximum daily dose of 1 mg of warfarin will be permitted for port line patency.  Should a thrombotic event occur while the subject is receiving treatment, the subject may continue, but low molecular weight heparin, dabigatran, or edoxaban will be the preferred treatment.   
● Subjects who develop hyperglycemia during the study should be treated as determined by the treating clinician, according to the American Diabetes Association guidelines.   
Other medications considered necessary for the subject’s safety and well -being may be given at 
the discretion of the investigator with the exception of those listed in Section  5.4.2 or 
Appendix H  and Appendix I.  
5.4.2 Prohibited Concomitant Medications  
The following treatments are prohibited while on this study:  
● No other investigational therapy should be given to subjects.  No anticancer agents other 
than the study medications should be given to subjects.  If such agents are required for a 
subject, then the subject must first be withdrawn from the study.  
● In vitro, H3B-6545 is a reversible and time-dependent inhibitor of CYP2C8, 2C9, 2C19, and CYP3A4.  Drugs with narrow therapeutic index and known to be metabolized by CYP2Cs or CYP3A4 are not permitted because of the inherent potential risk of either reduced activity or enhanced toxicity of the respective concomitant medication (Appendix H ).   
● H3B-6545 is a substrate of CYP3A4 and P-gp, thus medications that are strong inducers or inhibitors of CYP3A4 or P -gp ( Appendix H ) should be avoided.  For the most updated 
information, visit the following Web address:  http://medicine.iupui.edu/clinpharm/ddis/. 
● Due to a potential drug-drug interaction (DDI) , BCRP substrates with narrow therapeutic 
index are not permitted because H3B -6545 is an inhibitor of BCRP (but not a substrate) 
(Appendix H ). 
● If, after a subject has been enrolled, she requires the concomitant use of any of the medications that may cause QTc interval prolongation, then H3B-6545 must be held while 
 
CO N FI D E N TI A L  
ST U D Y D R U G :  H 3 B -6 5 4 5  
PR O T O C O L AM E N D M E N T 9:   2 9  AU G 2 0 2 2  P a g e 9 1  of 1 6 0  t h e s u bj e ct r e c ei v e s t h e c o n c o mit a nt m e di c ati o n ( A p p e n di x I ).   R e s u m pti o n of tr e at m e nt 
wit h H 3 B - 6 5 4 5 m a y b e c o n si d er e d f oll o wi n g di s c o nti n u ati o n a n d w a s h o ut ( at l e a st 5 h alf- 
li v e s) of t h e c o n c o mit a nt m e di c ati o n if t h e s u bj e ct h a s n ot pr o gr e s s e d a n d i s a gr e e d u p o n 
wit h t h e S p o n s or.  E x cl u d e d m e di c ati o n s t h at m a y c a u s e Q T c i nt er v al pr ol o n g ati o n ar e 
al s o li st e d a n d u p d at e d at t h e f oll o wi n g W e b a d dr e s s: htt p:// cr e di bl e m e d s. or g. 
● H er b al pr e p ar ati o n s/ m e di c ati o n s ar e n ot all o w e d t hr o u g h o ut t h e st u d y.  T h e s e h er b al 
m e di c ati o n s i n cl u d e, b ut ar e n ot li mit e d t o St. J o h n’ s w ort, k a v a, e p h e dr a ( m a h u a n g), 
gi n g k o bil o b a, D H E A, y o hi m b e, s a w p al m ett o, a n d gi n s e n g.  S u bj e ct s s h o ul d st o p u si n g 
t h e s e h er b al m e di c ati o n s 7 d a y s pri or t o fir st d o s e of st u d y dr u g.  
● S y st e mi c c orti c o st er oi d s ar e n ot all o w e d d uri n g t h e st u d y.  N ot e: T h e f oll o wi n g u s e s of 
c orti c o st er oi d s ar e p er mitt e d: si n gl e d o s e s, t o pi c al a p pli c ati o n s ( e g , f or r a s h), i n h al e d 
s pr a y s ( e g , f or o b str u cti v e air w a y di s e a s e s), e y e dr o p s, or l o c al i nj e cti o n s ( e g , i ntr a -
arti c ul ar).  S h ort c o ur s e s of s y st e mi c c orti c o st er oi d s m a y b e c o n si d er e d i n c o n s ult ati o n 
wit h t h e M e di c al M o nit or.  
6.  D O S E M O D I F I C A T I O N S  
If a n y t o xi cit y o c c ur s, it will b e gr a d e d utili zi n g t h e N CI C T C A E v 4. 0 3,  a n d a p pr o pri at e 
s u p p orti v e c ar e tr e at m e nt will b e a d mi ni st er e d t o d e cr e a s e t h e si g n s a n d s y m pt o m s t h er e of.  
D o s e a dj u st m e nt s will b e b a s e d o n t h e or g a n s y st e m e x hi biti n g t h e gr e at e st d e gr e e of t o xi cit y. 
6. 1  D o s e M o difi c ati o n s D u e t o T o xi cit y 
D o s e r e d u cti o n s or h ol d s a n d i niti ati o n of s u p p orti v e c ar e ar e all o w e d a s cli ni c all y i n di c at e d b y 
t h e tr e ati n g p h y si ci a n.  S u bj e ct s w h o r e q uir e a tr e at m e nt i nt err u pti o n d u e t o dr u g- r el at e d t o xi cit y 
f or m or e t h a n 4 w e e k s will di s c o nti n u e st u d y tr e at m e nt.  T r e at m e nt wit h H 3 B - 6 5 4 5 will b e h el d 
i n a n y s u bj e ct e x p eri e n ci n g a d o s e m o dif yi n g e v e nt a s d e s cri b e d i n S e cti o n 5. 1. 2  at a n y ti m e 
d uri n g t h e st u d y.  S u bj e ct s w h o e x p e ri e n c e a D L T i n P h a s e 1 C y cl e 1 a c c or di n g t o T a bl e 2 ab o v e 
will b e di s c o nti n u e d fr o m tr e at m e nt u nl e s s ot h er wi s e s p e cifi e d i n writi n g fr o m t h e S p o n s or.  
D o s e m o difi c ati o n s f oll o wi n g a d o s e m o dif yi n g e v e nt will b e a c c or di n g t o T a bl e 3 a n d T a bl e 4 
b el o w. 
T w o d o s e r e d u cti o n s  f or 
t o xi cit y will b e all o w e d.  I n a d diti o n, d o s e r e d u cti o n s will al s o b e all o w e d b a s e d o n cli ni c al 
j u d g m e nt of t h e tr e ati n g p h y si ci a n.  If p er si st e nt t o xi cit y o c c ur s d e s pit e t w o d o s e r e d u cti o n s, t h e 
s u bj e ct will di s c o nti n u e st u d y tr e at m e nt.   
 C CI 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 95 of 160 7. STUDY ASSESSMENTS AND EVALUATIONS  
7.1 Overview  
All subjects should visit the study site on the days specified within this protocol.  The complete 
Schedule of Assessments for this study is shown in Appendix D, Appendix E, and Appendix F.    
With Sponsor approval, in certain situations (eg, due to the COVID pandemic), and as per local regulations, certain assessments and study related activities may be performed remotely.  
Prescreening Visit - starting from Amendment 6 (or subsequent amendments):  
If all the following criteria  are satisfied:  
a) An ESR1 mutation status report is already available for the subject from one of the sponsor-designated laboratorie s based on cfDNA test report 
b) The blood sample for this report was drawn within 3 months of the date of main study consent 
c) The report clearly shows ESR1 Y537S mutation at an AF ≥0.5% in absence of ESR1 D538G at AF ≥0.5% (that is, clonal Y537S) 
Then the subject may  proceed to sign the main consent of the study and no prescreening blood 
sample is needed for re- testing the ESR1 mutation status.  
Otherwise, potential subjects will be asked to sign a prescreening consent in order to determine if their tumor carries a clonal  ESR1  Y537S mutation. Only after confirmation of the presence of a 
ESR1 Y537S mutation at an AF ≥0.5% and absence of ESR1 D538G at AF ≥0.5% from a 
sponsor-designated lab oratory will the subject be invited to sign the main study consent.   
-During the Prescreening Visit:  
● Pre-screening consent for the collection of a whole blood sample for cfDNA testing - 
● Collection of a whole blood sample for cfDNA testing  
If a redraw is necessary due to quality concerns at the analysis laboratory (eg , not acceptable for 
analysis), an add itional sample may be collected.  
-Study Informed Consent (Visit 1):  
In addition to the 2 previous scenarios, s ubjects may sign the main consent form if they have 
clonal ESR1  Y537S mutation, as defined above, based on a local laboratory report, but may not 
be dosed on C1D1 until their mutational status has been confirmed by a sponsor-designated cfDNA test from a blood sample obtained during the screening period. 
Informed consent (Visit 1) must be obtained ≤28 days prior to initiation of treatment and before 
any protocol- specific procedures are performed.  The screening physical examination, medical 
history, ECOG PS, complete blood counts (CBCs), differential and platelets, comprehensive 
metabolic profile (CMP) including liver (alkaline phosphatase [ ALP ], AST,  and ALT) and 
thyroid function ( thyroid -stimulating hormone [ TSH ] and Free T4) tests, urinalysis, and 
prothrombin time/partial thromboplastin time (PT/PTT) using international normalized ratio  
(INR) should be done ≤7 days prior to initiation of treatment (Study Visit 2).   
Whole blood and a pre- treatment biopsy will be collected at baseline for biomarker analysis.  
Subjects must be willing to undergo tumor biopsies prior to treatment and on Cycle 2 Day 1.  In 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 96 of 160 the Phase 2 part of the trial, subjects with bone-only disease, or subjects for whom a biopsy is 
contra-indicated, may opt out of providing tumor biopsies following investigator concern and discussion and approval from the Sponsor.  A urine or serum pregnancy test must be performed within 72 hours of Cycle 1 Day 1 for all pre-and peri-menopausal subjects.  Computed tomography (CT) scans (Visit 1) should be performed ≤28 days prior to initiation of treatment 
(Cycle 1 Day 1).  A bone scan (
99m-technetium-based scintigraphy, whole-body bone magnetic 
resonance imaging ( MRI ), or 18F-sodium fluoride position emission tomography [ NaF PET] ) to 
establish a baseline should be performed prior to first dose of study drug (a historical bone scan 
performed w ithin 6 weeks prior to the first dose is acceptable), and as clinically indicated.  
Lesions identified on bone scans should be followed with cross-sectional imaging. 
The prescreening and screening assessments described in Appendix D  and Appendix E, 
respectively, will be collected, reviewed, and determined to be acceptable by the site PI or 
designee after obtaining informed consent prior to the initiation of treatment. 
A cycle of treatment is scheduled to last 4 weeks (28 calendar days).   
Multiple procedure s may be scheduled at the same time point relative to H3B -6545 dosing.  
Priority should be given to PK collection at the time specified.  Vital signs and triplicate 
electrocardiogram (ECG) assessments should be performed prior to specimen collections.  
7.2 Base line Study Assessments (Visit 2)  
The following information will be collected and procedures will be performed for each subject at screening ≤7 days prior to initiation of treatment, unless otherwise noted: 
● Written ICF prior to any other study -related proce dures (≤28 days prior to initiation of 
treatment).  
● Assessment of inclusion/exclusion criteria.  
● Medical history, including cancer history, eg, date and stage at diagnosis, hormone receptor status, extent of disease, and all previous anti -cancer treatments , response to such 
treatments , best overall response, and the Time to Progression (TTP)  (per RECIST 1.1) for 
the most recent prior therapy . 
● A bone scan (
99m-technetium- based scintigraphy, whole -body bone MRI, or NaF PET) 
will be performed to establish a baseline (a historical bone scan performed within 6 weeks prior to the first dose of study drug is acceptable), and as clinically indicated.  Lesions identified on bone scans should be followed with cross- sectional imaging.  
● Physical examination, measurements of height (first visit only), weight, and vital signs (resting HR, BP, respiratory rate [RR] , and oral temperature).  
● ECOG PS ( Appendix A ). 
● 12-lead ECG in triplicate.  
● Echocardiogram/MUGA assessment (≤28 days prior to initiation of treatment). 
● Review and record concomitant medications (all concomitant medications taken within 28 days prior to Cycle 1 Day 1 should be documented in the eCRF). 
● CBC including hemoglobin, hematocrit, white blood count (WBC) with 5- part differential, 
and platelets plus reticulocytes.  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 97 of 160 ● CMP to include:  glucose, blood urea nitrogen (BUN), creatinine, sodium, potassium, 
chloride, calcium, magnesium, phosphorus, lactate dehydrogenase, carbon dioxide (CO2), ALP, AST, ALT, TSH, free T4, total bilirubin, total protein, and albumin.  
● PT/PTT.  
● Urine testing dipstick.  
● Serum or urine pregnancy test for all pre -and perimenopausal subjects (must be performed 
within 72 hours prior to the initiation of treatment).  
● Archived tumor tissue if available (see Section 7.8.2) .  For subjects enrolled under 
Amendment 6 (or subsequent amendments), a recent archival tumor tissue obtained within 6 months prior to enrollment or a fresh tumor biopsy must be provided. A second biopsy after initiating trial therapy is not required.  
● Whole blood for nucleic acids (cfDNA).  
● Tumor biopsy (unless contraindicated) 
● Transvaginal ultrasound (subjects in the Phase 2 endometrium sub-study only)  (≤14 days prior to initiation of treatment).  
● Disease assessment:  CT scan of chest, abdomen, and pelvis (≤28 days prior to initiation 
of treatment).  All study imaging for tumor assessments will be sent to an imaging core laboratory designated by the Sponsor for review of quality, and archived for potential independent review. 
 
7.3 Study Treatment Assessments  
7.3.1 Cycle 1 Days 1 (Visit 3), 8 (Visit 4), 15 (Visit 5), and 22 (Visit 6)  
For all subjects and all visits, unless otherwise stated:  
● Physical examination, measurements of weight, and vital signs (resting HR, BP, RR, and 
oral temperature) (Day 1 only). No need to repeat physical exams on Cycle 1 Day 1 if the 
baseline physical exam was performed ≤72 hours. 
● ECOG PS (Day 1 only).  
● 12-lead ECG or continuous Holter monitor:  
Phase 1: continuous Holter monitoring must begin at least 1 hour prior to dose on Cycle 1, Days 1 and 15, and continue through at least 24 hours post-dose.  For convenience, Holter monitoring may begin up to 12 hours prior to dosing on Cycle 1, Day 1 or Day 15.  
Phase 2:  in place of Holter monitoring, a 12- lead ECG will be performed in triplicate on 
Cycle 1, Days 1 and 15.  
o If sinus bradycardia is observed at any point during treatment (from ECG or other 
clinical assessment), it is recommended the subject undergo a stress test per institution policy. A stress test is recommended to be done only once for each subject who has under 60 beats per minute (while on treatment) and more than a 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 98 of 160 20 percent reduction from baseline in beats per minute. The stress test should be 
triggered by the previous two cardiac observations at rest. 
● Assessment and recording of AEs (from the time informed consent was signed).  
● Review and recording of concomitant medication (all concomitant medications taken 
within 28 days prior to Cycle 1 Day 1 should be documented in the eCRF) 
● CBC including hemoglobin, hematocrit, WBC with 5- part differential, and platelets plus 
reticulocytes. Do not repeat on Cycle 1 Day 1 if it is within 72 hours of baseline. 
● CMP.  Do not repeat on Cycle 1 Day 1 if it is within 72 hours of baseline. 
● PT/PTT.  
● Urine testing dipstick.  
● Phase 1 – PK samples for all subjects ( Days 1 and 15: collected at time points 0 (pre -
dose), 0.5 hr, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 10 hr, and 24 hr post-dose; Days 8 and 22: collected pre-dose only) ( See Section 7.7).   
● Phase 2 – PK samples for subjects in the food- effect sub -study: Days 15 and 22: collected 
at time points 0 (pre -dose), 0.5 hr, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 10 hr, and 24 hr post- dose) 
(See Section 7.7).   
● Phase 2 – All other subjects: Sparse PK samples will be performed on Day 15 following 
one of three schedules, assigned sequentially:  
o Schedule 1: pr e-dose (0 hr), 0.5 hr, and 6 hr post-dose 
o Schedule 2: pre -dose (0 hr), 2 hr, and 8 hr post- dose 
o Schedule 3: 1 hr, 4 hr, 24 hr post- dose (See Section 7.7).  Plasma fo r cfDNA 
(nucleic acids) on Days 1 and 15. 
o For subjects enrolled under Amendment 6 (and subsequent amendments), PK samples will be collected on Days 1 and 15 at pre -dose (0 hr) and at 1, 2, 4, and 6 
hours post-dose.   
● Whole blood for pharmacogenetics (PG) on Day 1 only.  
● Blood sample for markers of bone resorption and formation markers (anytime from screening period up to Day 1 pre-dose).  
● H3B-6545 administration.  
● Schedule next visits for the cycle (Day 1 only). 
7.3.2 Cycle 2 Days 1 (Visit 7) and 15 (Visit 8)  
Both visits unless otherwise stated:  
● Physical examination and vital signs (Day 1 only). 
● ECOG PS (Day 1 only). 
● 12-lead ECG in triplicate prior to dosing and 3  hours post-dose (Day 1 only). If sinus 
bradycardia is observed at any point during treatment (from ECG or other clinical assessment), it is recommended the subject undergo a stress test per institution policy. A stress test is recommended to be done only once for each subject who has under 60 beats 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 99 of 160 per minute (while on treatment) and more than a 20 percent reduction from baseline in 
beats per minute. The stress test should be triggered by the previous two cardiac observations at rest. 
● AE assessment.  
● Review  and recording of concomitant medication.  
● CBC including hemoglobin, hematocrit, WBC with 5- part differential, and platelets plus 
reticulocytes.  
● CMP.  
● PT/PTT.  
● Urine testing dipstick.  
● Serum or urine pregnancy test for all pre - and perimenopausal subjects (Day 1 only).  
● Tumor biopsy (unless contraindicated)  
o The subject must have received at least 7 days of consecutive dosing prior to collection of the second biopsy.  The window for collection of the Cycle 2 biopsy may be extended if needed in order to ensure 7 consecutive days of dosing prior to collection. 
● Whole blood for nucleic acids (cfDNA) on Day 1 only.  
● Blood sample for markers of bone resorption and formation on Day 15 only. 
● H3B-6545 administration.  
● Schedule next visit (Day 1 only). 
7.3.3 Cycle 3 Days 1 (Visit 9) and 15 (Visit 10)  
For all subjects, during both visits, unless otherwise stated:  
● Physical examination and vital signs (Day 1 only). 
● ECOG PS (Day 1 only). 
● 12-lead ECG in triplicate prior to dosing and 3 hours post-dose (Day 1 only). 
● AE assessment.  
● Review and recording of concomitant medication.  
● CBC including hemoglobin, hematocrit, WBC with 5- part differential, and platelets plus 
reticulocytes.  
● CMP (Day 1 only).  
● PT/PTT.  
● Urine testing dipstick.  
● Serum or urine pregnancy test for all pre -and perimenopausal subjects (Day 1 only).  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 100 of 160 ● Disease assessment: CT scan of chest, abdomen, and pelvis.  All study imaging for tumor 
assessments will be sent to an imaging core laboratory designated by the Sponsor for review of quality, and archived for potential independent review. 
● Whole blood for nucleic acids (cfDNA) on Day 1 of Cycle 3 and every other cycle thereafter  in conjunction with tumor imaging assessment. 
● H3B-6545 administration.  
● Schedule next visit (Day 1 only). 
7.3.4 Cycle 4 and Beyond - Days 1 (Visits 11, 13, 15, and beyond) and 15 (Visit 12)  
For all subjects, during s both visits, unless otherwise stated: 
● Physical examination and vital signs (Day 1 only). 
● ECOG PS (Day 1 only). 
● 12-lead ECG in triplicate prior to dosing and 3 hours post-dose (Cycle 4 Day 1 only). If sinus bradycardia is observed at any point during treatment (from ECG or other clinical assessment), it is recommended the subject undergo a stress test per institution policy. A stress test is recommended to be done only once for each subject who has under 60 beats 
per minute (while on treatment) and more than a 20 percent reduction from baseline in beats per minute. The stress test should be triggered by the previous two cardiac observations at rest.  
● AE assessment.  
● Review and recording of concomitant medication.  
● CBC including hemoglobin, hematocrit, WBC with 5- part differential, and platelets plus 
reticulocytes.  
● CMP (Day 1 only). 
● PT/PTT.  
● Urine testing dipstick.  
● Serum or urine pregna ncy test for all pre -and peri-menopausal subjects (Day 1 only). 
● Whole blood for nucleic acid (cfDNA) on Day 1 of Cycle 3 and every other cycle thereafter , in conjunction with tumor imaging assessment.   
● Blood samples for markers of bone resorption and formation (Cycle 4 Day 1 only, before dosing). 
● Transvaginal ultrasound (Cycle 4 Day 1 and then every 24 weeks until progression) (subjects in the Phase 2 endometrium sub-study only). 
● H3B-6545 administration. 
● Schedule next visit (Day 1 only) 
● Day 15 visits can be discontinued after Cycle 4 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 101 of 160 7.4 Response Assessment Every 8 Weeks 
Subjects will be evaluated for tumor response every 8 weeks (±1 week) with a CT scan of the 
chest, abdomen, and pelvis.  Subjects with a partial response  or CR will have a second 
confirmatory scan ≥ 4 weeks following the initial scan showing response. 
Subjects with progressive disease or unacceptable toxicity should discontinue trial therapy; 
subjects with stable disease (SD) or response to therapy will continue treatment.  
If a subject discontinues therapy for a reason other than radiological disease progression or withdrawal of consent, tumor assessment by CT and/or MRI scans should continue every 8 weeks (± 1 week)  until radiological disease progression or starting a new anti -cancer therapy.   
Refer to Section 7.6 a nd Appendix F  for the tumor assessment schedule for subjects in the 
Extension Phase.  
7.5 End-of-Treatment Visit 
Subjects are permitted to continue treatment with H3B -6545 until disease progression, 
unacceptable toxicity, or decision to discontinue treatment by the subject or the study physician.  Follow-up evaluations required after end of treatment are specified in  Appendix E.  
If treatment is discontinued because of toxicity or any other reason(s) at a treatment visit and no study treatment is administered, that visit may fulfill the EOT  visit.  
If a subject withdraws from treatment during Cycle 1 (28 calendar days) due to any reason other than a DLT and does not meet the minimum requirements for inclusion in the DLT- evaluable 
population described in Section  10.10,  that subject will be replaced.  
After discontinuation of trial therapy, subjects must be followed for any new AEs for 28  calendar 
days after the last dose of H3B -6545. 
The following EOT  visit procedures will be performed : 
● Physical examination, weight, and vital signs (resting HR, BP, RR, and oral temperature).   
● ECOG PS ( Appendix A ). 
● AE assessment.   
● Review and recording of concomitant medication.  
● CBC, including WBC with 3- part differen tial, and platelets.   
● CMP.  
● PT/PTT.  
● Urine dipstick.  
● 12-lead ECG in triplicate for all subjects. If sinus bradycardia is observed at the EOT visit, 
follow up ECGs should be performed weekly until HR returns 60 or more beats per minute or to pre -study baseline.   
● Disease assessment: CT scan of chest, abdomen, and pelvis.  All study imaging for tumor assessments will be sent to an imaging core laboratory designated by the Sponsor for review of quality, and archived for potential independent review. 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 102 of 160 ● Whole blood sample for nucleic acids (cfDNA).  
● Blood sample for markers of bone resorption and formation. 
7.6 Follow- up after End-of- Treatment Visit  
Subjects who discontinue treatment will be followed for safety for 28 days after the subject’s last 
dose.  Subjects must complete a safety follow -up visit on the 28th day (with up to + 7-day 
window).  During the safety follow -up visit the following should be obtained: vital signs, 
hematological and CMP laboratory parameters, and triplicate ECGs on ERT provided study equipment.  All AEs that occur during the safety follow-up period will be recorded.  
If sinus bradycardia is observed at EOT visit, follow up ECGs should be performed weekly until HR returns 60 or more beats per minute or to pre-study baseline. 
If a subject dis continues therapy for any reason other than radiological disease progression or 
withdrawal of consent, tumor assessments by CT and/or MRI scans should continue every 8 
weeks (± 1 week) until radiological disease progression or until they start a new anti -cancer 
therapy.   
There will be a data cutoff for the primary  analysis at 6 months after the last subject receives 
their first dose  of study treatment .  All subjects who are still on study treatment at that time will 
enter the Extension Phase. Following disease progression, all subjects will be followed for survival at least every 12 weeks 
and until the data cutoff for the primary  analysis, when  survival follow -up will end  for all 
subjects.  N o survival follow -up will be done in the Extension Phase.  Survival follow-up can be 
done by telephone call at the investigator’s discretion.  The first anti-cancer therapy following treatment discontinuation will be recorded  up until the data cutoff for the primary  analysis.  
Subjects may continue to receive treatment after progression only if, after a discussion with the medical monitor, it is determined that the subject continues to derive clinical benefit.  
In the Extension P hase , subjects still on study treatment will continue to receive study drug in 
28-day cycles until disease progression, development of unacceptable toxicity, subject request, withdrawal of consent, or discontinuation of study by the Sponsor.  Tumor assessments will be performed according to the local standard of care, but no less than every 12  weeks.  As per t he 
Schedule of Assessments for the Extension Phase, only safety and dosing information will be 
collected (Appendix F ). The End of Treatment Visit assessment will occur 28  (+ 7 days)  days 
after the final dose of study treatment.  All AE s/SAEs will be captured up to 28 days (+ 7 days) 
after the last dose of study drug.  
The end of study is the last subject’s last assessment  (eg, the last  assessment for the last subject 
in the Extension Phase) . 
7.7 Pharmacokinetics  
During the Phase 1 part of the trial, plasma samples will be collected during Cycle 1 on Day  1 
and Day 15 (pre-dose [0 hr], 0.5, 1, 2, 4, 6, 8, 10, and 24 hr post dose), for analysis of plasma 
concentration levels of H3B -6545 and potentially selected metabolite(s),  at the specified time 
points.  Additional pre-dose trough samples will be collected during Cycle 1 on Day 8 and Day 22.   
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 103 of 160 For the subjects enrolled in the food effect cohort of Phase 2 of the trial, plasma samples will be 
collected during Cycle 1 on Day 15 and Day 22 (pre-dose [0 hr], 0.5, 1, 2, 4, 6, 8, 10, and 24 hr post dose prior to the next dose).   
For all other Phase 2 subjects not enrolled in the food effect cohort, sparse PK samples will be 
collected on Day 15 following one of three schedules, assigned sequentially:  
● Schedule 1: pre -dose (0 hr), 0.5 hr, and 6 hr post-dose.  
● Schedule 2: pre -dose (0 hr), 2 hr, and 8 hr post-dose.  
● Schedule 3: 1 hr, 4 hr, and 24 hr post-dose.  
For subjects enrolled under Amendment 6 (or subsequent amendments), PK samples will be collected on Cycle 1 Days 1 and 15 at pre- dose (0 hr : -60 ~ 0 min) and at 1 (±10 min) , 2 (±15 
min), 4 ( ±20 min ), and 6 (±30 min) hours post- dose.  
Pharmacokinetic sample collection will end at the time of the data cutoff for the primary analysis (per Amendment 09).  
In Phase 1 and Phase 2, a protocol deviation will be reported only when a PK time point is not collected (missing) or blood is drawn on the wrong study day. 
Plasma concentrations of H 3B-6545 will be tabulated and summarized by dose level, day, and 
time.  Standard PK parameters including, but not limited to, the area under the plasma 
concentration -time curve from time point 0 through the last measurable point (AUC
0−t), C max, 
time of maximum  observed plasma concentration (t max), and accumulation ratio (R acc) will be 
determined.  If data permit, area under the plasma concentration -time curve extrapolated to 
infinity  (AUC 0-inf), t½, and apparent total body clearance following oral administration (CL/F) 
will be calculated.  Assessment of the effect of dose on  Cmax and AUC will also be performed.  
The primary assessment of PK will be done using non- compartmental methods; additional 
compartmental analysis may also be performed.  
The effect of a high -fat meal on AUC, C max and t max of H3B-6545 will be evaluated using a 
mixed linear model of logarithmically transformed values of the primary PK parameters.  Ratios of geometric means (fed/fa sted comparison) and associated 2 -sided 90% confidence intervals 
(CIs) will be presented.  
Plasma samples collected for PK analysis may also be used for an exploratory assessment of the H3B- 6545 metabolite profile.  A report for metabolite identification will be provided in a 
separate document, and results for metabolites will be not included in the clinical study report.  
Instructions for the processing, storage, and shipment of PK and metabolite identification 
samples will be provided in the Laboratory Manual.  For PK, plasma concentrations of analyte(s) will be quantified by liquid chromatography with tandem mass spectrometry (LC- MS/MS) 
methodology using a validated assay. 
7.8 Biomarkers  
Instructions for the collection, processing, storage, and shipping of samples will be provided in 
the Laboratory Manual.  Time points and minimum blood volume for biomarker specimens are presented in Table 5 . B iomarker sample  collection  will end at the time of the data cutoff for the 
primary analysis. 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 108 of 160 8.2 Storage Conditions 
All study drugs must be kept in a secure place under appropriate storage conditions.  Storage 
conditions for H3B-6545 are included on the investigational product label.  
The Sponsor or its representatives must be granted access on reasonable request to check drug storage, dispensing procedures, and accountability records. 
Study drug will be stored in accordance with the labeled storage conditions.  Continuous 
temperature monitoring and recording is required at the storage location to ensure that the study drug is maintained within an established temperature range.  The investigator or designee is responsible for ensuring that the temperature i s recorded while the drug is at the clinic and that 
records are maintained; the temperature should be monitored continuously by using either an in-house validated data acquisition system, a mechanical recording device, such as a calibrated chart recorder, or by manual means, such that minimum and maximum thermometric values over 
a specific time period can be recorded and retrieved as required.  When the H3B -6545 is 
dispensed to the subject, they will be asked to store the drug in the refrigerator.  
8.3 Accountability for All Study Drugs  
The PI (or designee) is responsible for accountability of all used and unused study drug supplies 
at the site.  Under no circumstances will the investigator allow the study drug to be used other than as directed by this p rotocol.  Study drug will not be dispensed to any individual who is not 
enrolled in the study. 
All study drug inventories must be made available for inspection by the Sponsor or its 
representatives and regulatory agency inspectors upon request. 
The site mu st maintain an accurate and timely record of the following: receipt of all study drug, 
dispensing of study drug to the subject, collection and reconciliation of unused study drug that 
are either returned by the subjects or shipped to site but not dispensed to subjects, and return of reconciled study drug to the Sponsor or (where applicable) destruction of reconciled study drug at the site.   
This includes but may not be limited to: (a) documentation of receipt of study drug, (b) study drug dispensing/return reconciliation log, (c) study drug accountability log, (d) all shipping service receipts, (e) documentation of returns to the Sponsor, and (f) certificates of destruction for any destruction of study drugs/study supplies that occurs at the site.  All form s will be 
provided by the Sponsor. 
Any comparable forms that the site wishes to use must be approved by the Sponsor. The study drug and inventory records must be made available, upon request, for inspection by a 
designated representative of the Sponsor or a representative of a health authority (eg , FDA, 
Medicines & Healthcare products Regulatory Agency ).  As applicable, all unused study drug and 
empty and partially empty containers from used study drug are to be returned to the investigator or designee by the subject and together with unused study drug that were shipped to the site but not dispensed to subjects are to be returned to the Sponsor’s designated central or local depot(s) during the study or at the conclusion of the study, unless provision is made by the Sponsor for destruction of study drug and containers at the site.   
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 109 of 160 Approval for destruction to occur at the site must be provided by the Sponsor in advance.  Upon 
completion of drug accountability and reconciliation procedures by the site’s personnel and documentation procedures by the Sponsor’s personnel, study drug that are to be returned to the Sponsor’s designated central or local depot(s) must be boxed and sealed and shipped back to the central or local depot(s) following all local regulatory requirements.  In some regions, study drug 
may be removed from the site and hand delivered to the central or local depot by Sponsor representatives.  Where study drugs are approved for destruction at the site, destruction will occur following the site’s standard procedures and certificates of destruction will be provided to the Sponsor. 
Drug accountability will be reviewed during site visits and at the completion of the study. At the end of the study, all Drug Accountability Record Form(s) will be completed by the site 
and sent to the Sponsor CRA or designee.  Please contact the Sponsor or CRA regarding disposal of any study drug. 
9. RESPONSE EVALUATIONS AND MEASUREMENTS  
Tumor assessments will be performed at baseline (within 28 days of starting trial therapy) and 
every 8 weeks after starting trial therapy until progression.   
Response and progression will be evaluated in this study using the RECIST version 1.1 (see 
Appendix G ).  Lesions are either measurable or non -measurable according to the criteria.  The 
term “evaluable” in reference to measurability will not be used, as it does not provide additional 
meaning or accuracy.  
The data cutoff for the primary  analysis will occur at 6 months after the last subject receives their 
first dose  (see Section 7.6) .  All subjects who are still on study treatment at that time will enter 
the Extension Phase. Tumor assessments will be performed according to the local standard of care, but no less than every 12 weeks.  The Schedule of Assessments for the Extension Phase is 
found in Appendix F. 
Following progression, all subjects will be followed for survival at least every 12 weeks, and 
survival follow -up will end 6 months after the last subject receives their first dose of  study 
treatment (at the time of data cutoff for the primary analysis) (as of Amendment 9), and no 
survival follow -up will be done in the Extension Phase.  Survival updates may be obtained via 
phone call to the subject or her family and the information should be documented in the subject’s file.  
10. STATISTICAL CONSIDERATIONS  
10.1 Statistical Design  
This is a multi -center, open -label, dose-escalation followed by dose expansion Phase 1/2 study of 
H3B-6545.  
The statistical analyses of study data are described in this section.  Further details of the 
analytical plan will be provided in the Statistical Analysis Plan (SAP), which will be finalized 
before database lock.  
 
CO N FI D E N TI A L  
ST U D Y D R U G :  H 3 B -6 5 4 5  
PR O T O C O L AM E N D M E N T 9:   2 9  AU G 2 0 2 2  P a g e 1 1 0  of 1 6 0  1 0. 2  P h a s e 1 P ri m a r y O bj e cti v e 
T h e pri m ar y o bj e cti v e of t h e P h a s e 1 p orti o n of t hi s st u d y i s t o:  
● D et er mi n e t h e M T D a n d/ or t h e R P 2 D of H 3 B- 6 5 4 5 i n w o m e n wit h l o c all y a d v a n c e d or 
m et a st ati c E R - p o siti v e, H E R 2 n e g ati v e br e a st c a n c er.  
1 0. 3  P h a s e 1 S e c o n d a r y O bj e cti v e s  
T h e s e c o n d ar y o bj e cti v e s of t h e P h a s e 1 p orti o n of t hi s st u d y ar e t o: 
● E v al u at e t h e s af e t y a n d t ol er a bilit y of H 3 B - 6 5 4 5 i n w o m e n wit h l o c all y a d v a n c e d or 
m et a st ati c ( E R) - p o siti v e, H E R 2- n e g ati v e br e a st c a n c er   
● C h ar a ct eri z e t h e pl a s m a P K of H 3 B - 6 5 4 5. 
● E sti m at e t h e effi c a c y of H 3 B - 6 5 4 5 i n t er m s of r e s p o n s e r at e, D o R, D C R, P F S, a n d O S.  
1 0. 4  P h a s e 1 E x pl o r at o r y O bj e cti v e s 
1 0. 5  P h a s e  2 P ri m a r y O bj e cti v e  
T h e pri m ar y o bj e cti v e of t h e P h a s e 2 p orti o n of t hi s st u d y i s t o: 
● E sti m at e t h e effi c a c y of H 3 B - 6 5 4 5 i n t er m s of b e st o v er all r e s p o n s e r at e, D o R, D C R, 
C B R, P F S, a n d O S i n s u bj e ct s wit h ( E R)- p o siti v e, H E R 2- n e g ati v e br e a st c a n c er a n d i n 
th o s e wit h a n d wit h o ut E R αm ut  (i n cl u di n g a cl o n al E S R 1  Y 5 3 7 S m ut ati o n). 
1 0. 6  P h a s e 2 S e c o n d a r y O bj e cti v e s  
T h e s e c o n d ar y o bj e cti v e s of t h e P h a s e 2 p orti o n of t hi s st u d y ar e t o: 
● F urt h er c h ar a ct eri z e t h e s af et y of H 3 B - 6 5 4 5 i n t hi s s u bj e ct p o p ul ati o n. 
● F urt h er c h ar a ct eri z e t h e P K of H 3 B -6 5 4 5.  At l e a st s p ar s e P K s a m pl e s will b e c oll e ct e d 
fr o m all s u bj e ct s o n st u d y . 
● E v al u at e t h e eff e ct of a hi g h -f at m e al o n t h e r el ati v e bi o a v ail a bilit y of H 3 B - 6 5 4 5. 
● A s s e s s t h e eff e ct of H 3 B - 6 5 4 5 o n s er u m b o n e t ur n- o v er m ar k er s, n a m el y B S A P (f or 
o st e o cl a st m et a b oli s m), PI N P (f or b o n e f or m ati o n), a n d C T X (f or b o n e r e s or pti o n). 
● A s s e s s t h e eff e ct of H 3 B - 6 5 4 5 o n e n d o m etri al t hi c k n e s s a n d ut eri n e v ol u m e.  T hi s 
o bj e cti v e will b e a s s e s s e d i n a s u b gr o u p of w o m e n wit h i nt a ct ut eri.  
1 0. 7  P h a s e 2 E x pl o r at o r y O bj e cti v e s  
T h e e x pl or at or y o bj e cti v e s of t h e P h a s e 2 p orti o n of t hi s st u d y ar e t o: C CI 
 
CO N FI D E N TI A L  
ST U D Y D R U G :  H 3 B -6 5 4 5  
PR O T O C O L AM E N D M E N T 9:   2 9  AU G 2 0 2 2  P a g e 1 1 1  of 1 6 0  1 0. 8  St u d y E n d p o i nt s  
1 0. 8. 1. 1  P h a s e 1  
T h e pri m ar y st u d y e n d p oi nt f or P h a s e 1 i s t h e o c c urr e n c e of D L T s a s a f u n cti o n of t h e d o s e of 
H 3 B - 6 5 4 5 f or d et er mi n ati o n of t h e M T D a n d/ or R P 2 D. 
S e c o n d ar y st u d y e n d p oi nt s f or P h a s e 1 ar e: 
● S af et y/t ol er a bilit y:  t h e t y p e a n d fr e q u e n c y of A E s a n d S A E s u si n g N CI C T C A E v 4. 0 3, a s 
w ell a s c h a n g e s i n cli ni c al l a b or at or y v al u e s, vit al si g n m e a s ur e m e nt s a n d E C G 
p ar a m et er s.  
● P K: st a n d ar d pri m ar y P K p ar a m et er s i n cl u di n g, b ut n ot li mit e d t o, t h e ar e a u n d er t h e 
pl a s m a c o n c e ntr ati o n -ti m e c ur v e fr o m ti m e p oi nt 0 t hr o u g h t h e l a st m e a s ur a bl e p oi nt 
( A U C 0 −t ), C m a x , t m a x  a n d R a c c .   
● Pr eli mi n ar y effi c a c y:  R e s p o n s e will b e d et er mi n e d b y t h e i n v e sti g at or a s s e s s m e nt s.  T h e 
f oll o wi n g e n d p oi nt s will b e d et er mi n e d : 
- O R R , d efi n e d a s t h e pr o p orti o n of s u bj e ct s a c hi e vi n g a b e st o v er all r e s p o n s e of 
c o nfir m e d p arti al or c o m pl et e r e s p o n s e ( p arti al r e s p o n s e + C R)   
- D o R , d efi n e d a s t h e ti m e fr o m t h e d at e of fir st d o c u m e nt e d C R/ p arti al r e s p o n s e  u ntil 
t h e fir st d o c u m e nt ati o n of c o nfir m e d di s e a s e pr o gr e s si o n or d e at h, w hi c h e v er c o m e s 
fir st.   
- D C R , d efi n e d a s t h e pr o p orti o n of s u bj e ct s a c hi e vi n g a b e st r e s p o n s e of C R or p arti al 
r e s p o n s e , or S D  
- P F S , d efi n e d a s t h e ti m e fr o m fir st d o s e d at e t o t h e d at e of t h e fir st d o c u m e nt ati o n of 
c o nfir m e d di s e a s e pr o gr e s si o n or d e at h ( w hi c h e v er o c c ur s fir st).  
- O S , d efi n e d a s t h e ti m e fr o m fir st d o s e d at e t o t h e d at e of d e at h ( e v e nt) or d at e l a st 
k n o w n ali v e ( c e n s or e d).   
E x pl or at or y st u d y e n d p oi nt s f or P h a s e 1 a n d P h a s e 2 ( e x c e pt w h er e n ot e d) i n cl u d e: C CI 
C CI 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 117 of 160 Safety data to be evaluated include AEs, clinical laboratory results, vi tal sign measurements, and 
ECG parameters.  
Safety parameters will be summarized using descriptive statistics (mean, standard deviation, 
median, Q1, Q3, and range for continuous variables; numbers and percentages for categorical measures).  
The effects of H3 B-6545 on cardiovascular re- polarization will be evaluated via a 12 -lead 
continuous Holter.  On Cycle 1, Day 1 and Day 15, monitoring via Holter will begin at least 1 hour prior to dose and continue through at least 24 hours postdose for Phase 1 subjects only.   
For convenience, Holter monitoring may begin up to 12 hours prior to dosing on Cycle 1, Day 1 
or Day 15.  Individual ECGs will be extracted in triplicate from the Holter recordings at specified time points and will be evaluated by a central laborato ry.  QT intervals will be 
measured from Lead II and will be corrected for HR (QTc) using Fridericia's (QTcF) correction 
factors.  The primary QTc parameter will be QTcF.  Secondary parameters (QTc interval using Bazett’s correction factor (QTcB), QT, QRS  interval, and HR) and waveforms (T waves) will be 
evaluated. 
In addition, the  effects of H3B -6545 on the cardiovascular system will be evaluated via 12- lead 
ECG at screening and on Day 1 and Day 15 of Cycle 1, and Day 1 of Cycle 2, 3 and 4 as well as 
at the End of Treatment visit for all subjects (Phase 1 and Phase 2 subjects).  If sinus bradycardia is observed at EOT visit, follow up ECGs should be performed weekly until HR has returned 60 or more beats per minute or pre -study baseline. QT intervals will be measured from Lead II and 
will be corrected for HR (QTc) using Fridericia's  (QTcF) correction factor.  The primary QTc 
parameter will be QTcF; secondary parameters (QTc corrected using Bazett’s formula, QT, QRS  
interval, and HR) and waveforms (T waves) will be evaluated.  
10.11.5.1 Extent of Exposure 
Descriptive statistics for subjects trea ted, including the duration of treatment, the number of 
cycles received, and the number of subjects requiring dose changes, will be presented.  A by-subject listing of the date of study drug administration and the dose administered will be presented.  
10.11.5.2 Adver se Events  
AEs will be collected for each subject until 28 days after last trial therapy administration.  The 
NCI CTCAE v4.03 will be used for AE reporting.  
The AE verbatim descriptions (investigator terms from the CRF) will be classified into 
standardized  medical terminology using MedDRA.  Adverse events will be coded to the 
MedDRA (Version 19.1 or higher) lower level term closest to the verbatim term.  The linked MedDRA preferred term  and primary SOC are also captured in the database.  
A TEAE is defined as:  
- An AE that emerges during treatment, having been absent at pretreatment (baseline), or  
- Re-emerges during treatment, having been present at pretreatment (baseline) but stopped 
before treatment, or  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 118 of 160 - Worsens in severity during treatment relative to the pretreatment state, when the AE is 
continuous.  
Only those AEs that were treatment -emergent will be included in summary tables.  All AEs, 
treatment- emergent or otherwise, will be presented in subject data listings.  The TEAEs will be 
summarized for each study phase.  The incidence of TEAEs will be reported as the number (percentage) of subjects with TEAEs by SOC and preferred term.  
A subject will be counted only once within a SOC and preferred term, even if the subject experienced more than 1 TEAE within a specific SOC and preferred term .  The number 
(percentage) of subjects with TEAEs will also be  summarized by maximum CTCAE grade and 
by relationship to study drug (Yes [related] and No [not related]).  
The number (percentage) of subjects with TEAEs leading to death will be summarized by MedDRA SOC and preferred term for each study phase.  A subject data listing of all AEs leading 
to death will be provided.  The number (percentage) of subjects with treatment- emergent SAEs 
will be summarized by MedDRA SOC and preferred term for each study phase.  A subject data 
listing of all SAEs will be provided.  Th e number (percentage) of subjects with TEAEs leading 
to discontinuation from study drug will be summarized by MedDRA SOC and preferred term for each study phase.  A subject data listing of all AEs leading to discontinuation from study drug will be provided. 
In the Dose- Evaluable Set, the number (percentage) of subjects with DLTs will be presented by 
dose level for Phase 1 of the study.  A listing of subjects with DLTs will be provided.  
AEs will be summarized using the Safety Analysis Set.  The number of AEs  and number and 
incidence (%) of subjects with AEs will be summarized by cohort/dose level and overall.  To 
obtain the incidence (%), the number of subjects with at least 1 event and the percentage of subjects with AEs by SOC and by preferred term will be calculated.  Incidence (%) by causal 
relationship with study drug and by severity (CTCAE v 4.03) will also be calculated.  For clinically significant events, time of onset, and recovery will be reported.    
10.11.5.3 Laboratory Values 
Laboratory results will be summarized using Système International (SI) units, as appropriate.   
For all quantitative parameters listed, the actual value and the change from baseline to each post -
baseline visit and to the end of treatment (defined as the last on- treatment value) will be 
summarized by visit using descriptive statistics.  Qualitative parameters listed will be summarized using frequencies (number and percentage of subjects), and changes from baseline to each post-baseline visit and to end of treatment will be reported using shift tables.  Percentages will be based on the number of subjects with both non- missing baseline and relevant 
post- baseline results.  
Furthermore, the frequency of laboratory abnormalities by maximum post- baseline CTCAE 
grade will be tabulated by cycle and overall for selected laboratory parameters to include at least,
  
hemoglobin , WBC, absolute neutrophil count, lymphocytes, platelet count,  ALP, AST, ALT,   
bilirubin, creatinine, and electrolytes.  Shift tables will also be produced for these parameters  
based on the baseline CTCAE grade and the maximum CTCAE grade by cycle and overall. 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 119 of 160 10.11.5.4 Vital Signs  
Changes in vital sign parameters (including systolic and diastolic BP, HR, RR, and temperature) 
and body weight will be summarized over time, and any abnormal values will be tabulated.   
Descriptive statistics for vital signs parameters (ie, systolic and diastolic BP, pulse, RR, temperature, and weight) and changes from baseline will be presented by visit.  
10.11.5.5 Electrocardiograms  
ECG assessments will be performed thr oughout the study.  Descriptive statistics for ECG 
parameters and changes from baseline will be presented by visit.   
For all subjects, shift tables will present changes in ECG interpretation (categorized as normal; abnormal, not clinically significant; an d abnormal, clinically significant) from baseline to end of 
treatment.  In addition, summary tables and listings for the various intervals (eg , QT and PR) and 
changes from baseline will be presented.  
In addition, the number (percentage) of subjects with a t least 1 post -baseline abnormal ECG 
result in QTcF during the treatment period will be summarized.  Clinically abnormal ECG results in QTcF will be categorized as follows:  
Absolute QTc interval prolongation: 
- QTc interval >450 msec 
- QTc interval >480 msec  
- QTc interval >500 msec 
Change from baseline in QTc interval:  
- QTc interval increases from baseline >30 msec  
- QTc interval increases from baseline >60 msec  
All ECG abnormalities will be listed on a per- subject basis.   
10.11.6 Pharmacokinetic, Pharmacodynamic, Pharmacogenomic, and Other  Biomarker Analyses 
10.11.6.1 Pharmacokinetic Analyses  
Plasma concentrations of H3B-6545 will be tabulated and summarized by dose level, day, and time.   
H3B- 6545 PK parameters will be derived from plasma concentrations by noncompartmental 
analysis using actual times.  Minimally, the following PK parameters will be calculated: C
max, 
tmax, AUC 0-t, Racc, and if data permit, area under the plasma concentration- time curve 
extrapolated to infinity (AUC 0-inf), t½, CL/F, and V z/F. 
The effect of a high -fat meal on AUC and C max of H3B-6545 will be evaluated using a mixed 
linear model of logarithmically transformed values of the primary PK parameters.  Ratios of geometric means (fed/fasted comparison) and associated 2-sided 90% CIs will be presented.   
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 121 of 160 declare an MTD and/or RP2D, escalate or de- escalate the dose, and/or recruit additional subjects 
at the current or previous dos e levels. The SRC may be convened earlier at the discretion of the 
Sponsor if important safety issues arise requiring the attention of the committee.  
During the Phase 2 part of the trial, the SRC will receive all available safety data approximately 
every 6 months.  
11. SAFETY REPORTING  
Safety assessments will consist of monitoring and recording all AEs, including all Common Terminology Criteria for Adverse Events (CTCAE) v 4.03 grades (for both increasing and decreasing severity), and SAEs; regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and ECGs; and performance of physical examinations as detailed in Appendix D, Appendix E, and Appendix F. 
The PI is responsible for recognizing and reporting AEs to the Sponsor or designee.  It is the Sponsor’s responsibility to report relevant SAEs to the applicable local, national, or international regulatory bodies.  In addition, investigators must report SAEs and follow-up information to their responsible IRB/EC according to the policies of that IRB/EC.  
The PI is also responsible for ensuring that every staff member involved in the study is familiar with the content of this section.  
11.1 Definitions  
11.1.1 Adverse Events  
An AE is any untoward medical occurrence in a subject or clinical investigation subject administered an investigational product.  An AE does not necessarily have a causal relationship with the medicinal product.  For this study, the study drug is H3B-6545. 
The criteria for identifying AEs in this study are:  
● Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of an investigational product, 
whether or not considered related  to the investigational product (Note:  Every sign or 
symptom should not be listed as a separate AE if the applicable disease [diagnosis] is 
being reported as an AE). 
● Any new disease or exacerbation of an existing disease.  However, worsening of the primary disease should be captured under efficacy assessments as disease progression rather than as an AE, unless the event meets criteria for a serious AE as outlined in Section 11.1.2.  In such cases, the event should be reported as an SAE. 
● Any deterioration in non-protocol- required measurements of a laboratory value or other 
clinical test (eg , ECG or x -ray) that results in symptoms, a change in treatment, or 
discontinuation of study drug. 
● Recurrence of an intermittent medical condition (eg , headache) not present pre- treatment 
(Baseline)  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 122 of 160 ● An abnormal laboratory test result should be considered an AE if the identified laboratory 
abnormality leads to any type of intervention, withdrawal of study drug, or withholding of study drug, whether prescribed in the protocol or not. 
All AEs, regardless of relationship to study drug or procedure, should be recorded beginning from the time the subject signs the study ICF through 28 days af ter the last dose of drug . 
Abnormal laboratory values should not be listed as separate AEs if they are considered to be part of the clinical syndrome that is being reported as an AE.  It is the responsibility of the investigator to review all laboratory findings in all subjects and determine if they constitute an AE.  Medical and scientific judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an AE.  Any laboratory abnormality considered to constitute a n AE should be reported on the Adverse Event CRF.  
Abnormal ECG (QTcF) results, if not otherwise considered part of a clinical symptom that is being reported as an AE, should be considered an AE if the QTcF interval is more than 450 msec and there is an increase of more than 60  msec from baseline.  Any ECG  abnormality that the 
investigator considers as an AE should be reported as such.  Note: If sinus bradycardia is observed at EOT visit, follow up ECGs should be performed weekly until HR has returned 60 or 
more beats per minute or pre- study baseline.  
All AEs must be followed for 28 days after the subject’s last dose.  All SAEs must be followed to resolution or, if resolution is unlikely, to stabilization.
  
Every effort must be made by the investigator to categorize each AE according to its severity and its relationship to the study treatment.  
Assessing Severity of Adverse Events 
Adverse events will be graded on a 5 -point scale according to CTCAE v 4.03.  Investigators will 
report CTCAE grades for all AEs (for both increasing and decreasing severity). 
Assessing Relationship to Study Treatment  
Items to be considered when assessing the relationship of an AE to the study treatment are: 
● Temporal relationship of the onset of the event to the initiation of the study treatment  
● The course of the event, especially  the effect of discontinuation of study treatment or 
reintroduction of study treatment, as applicable  
● Whether the event is known to be associated with the study treatment or with other 
similar treatments  
● The presence of risk factors in the study subject known to increase the occurrence of the event 
● The presence of non- study treatment -related factors that are known to be associated with 
the occurrence of the event.  
Classification of Causality  
The relationship of each AE to the study drug will be recorded on the CRF in response to the following question: 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 123 of 160 Is there a reasonable possibility that the study drug caused the AE? 
Yes (related)  A causal relationship between the study drug and the AE is a reasonable 
possibility. 
No (not related ) A causal relationship between the study drug and the AE is not a reasonable 
possibility. 
Adverse Events of Special Interest  
Hy’s Law is the only reportable AESI for this protocol and events of Hy’s Law should be reported as outlined in Section 11.2. 
11.1.2 Serious Adverse Event  
A serious adverse event (SAE) is any untoward medical occurrence that at any dose:  
● Results in death.  
● Is life -threatening (ie, the subject was at immediate risk  of death from the adverse event 
as it occurred; this does not include an event that, had it occurred in a more severe form 
or was allowed to continue, might have caused death). 
● Requires inpatient hospitalization or prolongation of existing hospitalization . 
● Results in persistent or significant disability/incapacity.  
● Is a congenital anomaly/birth defect (in the child of a subject who was exposed to the study drug). 
Other important medical events that may not be immediately life -threatening or result in death  or 
hospitalization but, when based on appropriate medical judgment, may jeopardize the subject or may require intervention to prevent one of the outcomes in the definition of SAE listed above should also be considered SAEs.   
For example, an isolated laboratory abnormality could be considered to meet the criteria for 
serious (eg , if the event results in hospitalization or is considered medically significant).  
Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in such situations.  
In addition to the above, events associated with special situations include pregnancy or exposure to study drug through breastfeeding; AEs associated with study drug overdose, misuse, abuse, or medication error.  These events associated with special situat ions are to be captured using the 
SAE procedures but are to be considered as SAEs only if they meet one of the above criteria.  All AEs associated with special situations are to be reported on the CRF whether or not they meet the criteria for SAEs.   
All SAEs must be followed to resolution or, if resolution is unlikely, to stabilization.  
The following hospitalizations are not considered to be SAEs because there is no “adverse event” (ie, there is no untoward medical occurrence) associated with the hospitali zation: 
● Hospitalizations for respite care.  
● Planned hospitalizations required by the protocol. 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 124 of 160 ● Hospitalization planned before informed consent (where the condition requiring the 
hospitalization has not changed after study drug administration). 
● Hospitalizat ion for administration of study drug or insertion of access for administration 
of study drug. 
● Hospitalization for routine maintenance of a device (eg , battery replacement) that was in 
place before study entry 
It is important to distinguish between “serious ” and “severe” AEs, as the terms are not 
synonymous.  Severity is a measure of intensity; however, an AE of severe intensity need not necessarily be considered serious.  Seriousness serves as the guide for defining regulatory reporting obligations.  It is based on subject/event outcome or action usually associated with 
events that pose a threat to a subject’s life or vital functions.   
For example, nausea, which persists for several hours, may be considered severe nausea, but may not be considered an SAE.  On the other hand, a stroke, which results in only a limited degree of disability, may be considered only a mild stroke, but it would be considered an SAE.  Severity and seriousness should be independently assessed when recording AEs on the eCRF screen and  
SAEs on the SAE Report Form. 
11.1.3 Adverse Reaction  
An adverse reaction (AR) means any AE caused by a drug.  Adverse reactions are a subset of all 
SARs where there is a reason to conclude that the drug caused the event.  
11.1.4 Suspected Adverse Reaction  
Suspected adverse reaction (SAR) means any AE for which there is a reasonable possibility that the drug caused the AE.  Reasonable possibility means that there is evidence to suggest a causal relationship between the drug and the AE.  An SAR implies a lesser degree of certainty about causality than an AR, which means any AE caused by a drug. 
11.1.5 Recording and Reporting of Adverse Events  
Recording of Adverse Events 
All AEs of any subject during the course of the research study will be recorded in the eCRF, and 
the investigator will give his or her opinion as to the relationship of the AE to the study drug treatment (ie , whether the event is related or unrelated to study drug administration).  
All AEs should be documented.  A description of the event, including its date of onset and resolution, whether it constitutes an SAE or not, any action taken (eg, changes to study treatment), and outcome, should be provided, along with the investigator’s assessment of causality (ie, the relationship to the study treatment[s]).  For an AE to be a suspected treatment -
related event, there should be at least a reasonable possibility of a causal relationship between the protocol treatment and the AE.  Adverse events will be graded according to the NCI CTCAE v4.03, and changes will be documented. 
If the AE is serious or of special interest (eg , a case of Hy’s Law), it should be reported 
immediately to the Sponsor or designee. Other untoward events occurring in the framework of a 
clinical study are to be recorded as AEs (ie, AEs that occur prior to  assignment of study 
treatment that are related to a protocol-mandated intervention, including invasive procedures such as biopsies, medication washout, or no treatment run- in). 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 125 of 160 Any clinically significant signs and symptoms, abnormal test findings, changes in physical 
examination, hypersensitivity, and other measurements that occur will be reported as AEs and recorded on the relevant eCRF screen.  
Test findings will be reported as an AE if the test results require an adjustment in the study drug(s) or discontinuation of treatment, test findings require additional testing or surgical intervention; a test result or finding is associated with accompanying symptoms; and/or a test result is considered to be an AE by the investigator. 
Reporting Period for Adverse Events  
All AEs, regardless of relationship to study drug or procedure, should be recorded beginning 
from the time the subject signs the study ICF through 28 days after the last dose of drug.  SAEs will be collected for 28 days after the last dose.   
All AEs resulting in discontinuation from the study should be followed until resolution or stabilization.  All new AEs occurring during this period must be reported and followed until resolution unless, in the opinion of the investigator, the AE or laboratory abnormality(ies) are not likely to improve because of the underlying disease.  In this case, the investigators must record his or her reasoning for this decision in the subject’s medical record and as a comment on the eCRF screen.   
After 28 days of completion of protocol-specific treatment or discontinuation, only AEs, SAEs, or deaths assessed by the investigator as treatment related are to be reported.  
11.1.5.1 Regulatory Reporting of Adverse Events 
Adverse events will be reported by the Sponsor or a third party acting on behalf of the Sponsor to regulatory authorities in compliance with local and regional law and established guidance.  The format of these reports will be dictated by the local and regional requirements.  
11.2 Serious Adverse Event Reporting b y Investigators 
All SERIOUS ADVERSE EVENTS and adverse events of special interest (AESI), 
regardless of their relationship to study treatment, must be reported on a completed SAE 
form by email or fax as soon as possible but not later than 24 hours from whe n the investigator 
becomes aware of the event.   
SAEs, regardless of causality assessment, must be collected through the last visit.  SAEs will be 
collected for 28 days after the last dose .  All SAEs must be followed to resolution or, if 
resolution is unlikely, to stabilization.  Any SAE judged by the investigator to be related to the study treatment or any protocol-required procedure should be reported to the Sponsor regardless of the length of time that has passed since study completion.  
The detailed cont act information for reporting of SAEs is provided in the Investigator Study File.  
For urgent safety issues, please ensure all appropriate medical care is administered to the subject and contact the appropriate study team member listed in the Investigator Study File.  
It is very important that the SAE report form be filled out as completely as possible at the time of the initial report.  This includes the investigator’s assessment of causality.  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 126 of 160 Any follow-up information received on SAEs should be forwarded within 24 hours of its receipt.  
If the follow -up information changes the investigator’s assessment of causality, this should also 
be noted on the follow- up SAE form.  
Preliminary SAE reports should be followed as soon as possible by detailed descriptions including copies of hospital case reports, autopsy reports, and other documents requested by the Sponsor. 
Transmission of the SAE report should be confirmed by the site personnel submitting the report. Follow-up information for SAEs and information on non- serious AEs that become serious should 
also be reported as soon as it is available; these reports should be submitted using the SAE 
Report Form.  The detailed SAE reporting process will be provided to the sites in the SAE reporting guidelines contained in the study reference manual. 
Investigators must report SAEs and follow-up information to their responsible IRB according to 
the policies of the responsible IRB. 
11.2.1 Investigator Reporting After Study Discontinuation  
Twenty -eight days after completing protocol-specific treatment or study discontinuation, 
treatment- related AEs, SAEs, or deaths determined by the investigator as treatment -related are to 
be reported to the Sponsor or designee. 11.3 Recording of Adverse Events and Serious Adverse Events 
11.3.1 Diagnosis V ersus Signs and Symptoms  
All AEs should be recorded individually in the subject’s own words (verbatim) unless, in the 
opinion of the PI or designated physician, the AEs constitute components of a recognized condition, disease, or syndrome.  In the latter case, the condition, disease, or syndrome should be named rather than each individual sign or symptom.  If a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, each individual event should be recorded as an AE or SAE as appropriate on the relevant form(s) (SAE Report Form and/or AE eCRF screen).  
If a diagnosis is subsequently established, it should be reported as follow-up information is available.  If a diagnosis is determi ned subsequent to the reporting of the constellation of 
symptoms, the signs/symptoms should be updated to reflect the diagnosis. 
11.3.2 Persistent or Recurrent Adverse Events  
A persistent AE is one that extends continuously, without resolution, between subject evaluation 
time points.  Such events should only be recorded once on the SAE Report Form and/or the AE eCRF screen.  If a persistent AE becomes more severe or lessens in severity, it should be recorded on a separate SAE Report Form and/or AE eCRF screen.  
A recurrent AE is one that occurs and resolves between subject evaluation time points, and 
subsequently recurs.  All recurrent AEs should be recorded on an SAE Report Form and/or AE eCRF screen.  
11.3.3 Abnormal Laboratory Values 
If an abnormal laboratory value or vital sign is associated with clinical signs and/or symptoms, the sign or symptom should be reported as an AE or SAE, and the associated laboratory value or 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 127 of 160 vital sign should be considered additional information that must be collected on the relevant 
eCRF screen.  If the laboratory abnormality is a sign of a disease or syndrome, only the diagnosis needs to be recorded on the SAE Report Form or AE eCRF screen. 
Abnormal laboratory values will be reported as an AE if the laboratory result requires an 
adjustment in the study drug(s) or discontinuation of treatment; laboratory findings require additional testing or surgical intervention; a laboratory result or finding is associated with accompanying symptoms; and/or a laboratory result is considered to be an AE by the investigator.  
11.3.4 Deaths  
All on -study treatment deaths, regardless of attribution during the AE reporting period, will be 
recorded on an SAE Report Form and expeditiously reported. 
When recording an SAE with an outcome of death, the event or condition that caused or 
contributed to the fatal outcome should be recorded as the single medical concept on the SAE Report Form and Adverse Event screen of the eCRF.  If the cause of death is unknown and cannot be ascertained at the time of reporting, record “Death NOS” on the eCRF Adverse Event screen.   
During post- study treatment survival follow -up (after the 28 -day post-dose AE reporting period), 
deaths attributed to progression of disease will be recorded only on the “After Pro gressive 
Disease Follow -Up” eCRF screen.  
11.3.5 Hospitalization, Prolonged Hospitalization, or Surgery  
Any AE that results in hospitalization of >24 hours or prolongation of pre -existing 
hospitalization should be documented and reported as an SAE unless specifically instructed otherwise in this protocol.  There are some hospitalizations that do not require reporting as an SAE.  
Treatment within or admission to the following facilities is not considered to meet the criteria of 
“inpatient hospitalization” (although if any other SAE criteria are met, the event must still be 
treated as an SAE and immediately reported):  
● Emergency department or emergency room.  
● Outpatient or same -day surgery units. 
● Observation or short-stay unit. 
● Rehabilitation facility.  
● Hospice or skilled nursing facility.  
● Nursing homes, custodial care or respite care facility . 
Hospitalization during the study for a pre-planned surgical or medical procedure (one which was planned prior to entry in the study), does not require reporting as a SAE. 
11.3.6 Pre-Existing Medical Conditions  
A pre -existing medical condition is one that is present at the start of the study.  Such conditions 
should be recorded on the General Medical History of the eCRF screen.  A pre- existing medical 
condition should be recorded as an AE or SAE only if the frequency, severity, or character of the 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 128 of 160 condition worsens during the study.  When recording such events on an SAE Report Form and/or 
AE eCRF screen, it is important to convey the concept that the pre -existing condition has 
changed by including applicable descriptors. 
11.3.7 New Cancers  
The development of a new primary cancer should be regarded as an AE and will generally meet at least one of the seriousness criteria.  New primary cancers are those that are not the primary reason for the ad ministration of the study treatment and have developed after the inclusion of the 
subject into the study.  They do not include metastases of the original cancer.   
11.3.8 Pregnancy, Abortion, Birth Defects/Congenital Anomalies 
Any pregnancy in a female subject in  which the estimated date of conception is either before the 
last visit or within 28 days of last study treatment, or any exposure to study drug through 
breastfeeding during study treatment or within 28 days of last study treatment, must be reported . 
If an adverse outcome of a pregnancy is suspected to be related to study drug exposure, this 
should be reported regardless of the length of time that has passed since the exposure to study treatment.  
A congenital anomaly, death during perinatal period, an induced abortion, or a spontaneous abortion are considered to be an SAE and should be reported in the same time frame and in the same format as all other SAEs (see Reporting of Serious Adverse Events in  Section 11.2).  
Pregnancies or exposure to study drug through breastfeeding must be reported by fax or email as soon as possible but no later than 1 business day from the date the investigator becomes aware of the pregnancy.  The contact information for the reporting of pregnancies and exposure to study drug through breastfeeding is provided in the Investigator Study File.  The Pregnancy Report Form must be used for reporting.  All pregnancies must be followed to outcome.  The outcome of the pregnancy must be reported as soon as possible but no later than 1 business day from the date the investigator becomes aware of the outcome.  
A subject who becomes pregnant must be withdrawn from the study. 
The detailed contact information for reporting of pregnancies is provided in the Investigator 
Study File. If a subject becomes pregnant while enrolled in the study, a Pregnancy Form should 
be completed and submitted expeditiously, irrespective of whether or not it meets the criteria for expedited reporting.  Abortions (spontaneous, accidental, or therapeutic) must also be reported. 
Congenital anomalies/birth defects always meet SAE criteria, and should therefore be 
expeditiously reported as an SAE, using the previously described process for SAE reporting.  A Pregnancy Form should also have been previously completed and will need to be updated to reflect the outcome of the pregnancy.  
11.3.9 H3B-6545 Overdose 
Adverse events associated with study drug overdose, misuse, abuse, and medication error ref er to 
AEs associated with uses of the study drug outside of that specified by the protocol.  Overdose, misuse, abuse, and medication error are defined as follows:  
Overdose  Accidental or intentional use of the study drug in an amount higher than 
the protocol-defined dose 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 129 of 160 Misuse  Intentional and inappropriate use of study drug not in accordance with the 
protocol.  
Abuse  Sporadic or persistent intentional excessive use of study drug accompanied by harmful physical or psychological effects. 
Medication error  Any unintentional event that causes or leads to inappropriate study drug 
use or subject harm while the study drug is in the control of site personnel or the subject.   
All AEs associated with overdose, misuse, abuse, or medication error should be captured on the Adverse Event CRF and also reported using the procedures detailed in Reporting of Serious Adverse Events even if the AEs do not meet serious criteria.  Abuse is always to be captured as an AE.  If the AE associated with an overdose, misuse, abuse, or medication error does not meet serious criteria, it must still be reported using the SAE form and in an expedited manner but should be noted as nonserious on the SAE form and the Adverse Event CRF. 
Symptomatic and non- symptomatic overdose must be reported in the eCRF system.  Any 
accidental or intentional overdose with the study treatment that is symptomatic, even if not 
fulfilling a seriousness criterion, is to be reported no greater than 24 hours from first knowledge of the event using the correspond ing screens in the eCRF and following the same process 
described for SAE reporting (see Section 11.2) if the overdose is symptomatic.  
For information  on how to manage an overdose of H3B-6545, refer to the IB. 
11.4 Cardiovascular 
Triplicate 12 -lead ECGs will be collected approximately 5 minutes apart at the screening visit, 
and prior to dosing and 3-hour post dose on Day 1 and Day 15 of Cycle 1, and Day 1 of Cycle 2, Cycle 3, and Cycle 4, as well as at the end of treatment for all subjects (Phase 1 and Phase 2 subjects).  12- lead safety ECGs will be performed locally from Day 1 of each cycle starting 
Cycle 5 till the last cycle prior to the EOT visit, and at Unscheduled visits as clinically required.  
A single 12- lead safety ECG is required at a minimum.  Data from local safety ECGs should be 
entered into the clinical database.  
In addition, in the event of any alteration or if clinically indicated, additional ECGs and/or cardiac enzyme evaluations should be performed. If sinus bradycardia is observed at EOT visit, follow up ECGs should be performed weekly until heart rate has returned to 60 or more beats per minute or pre-study baseline. 
An ECG abnormality may  meet the criteria of an AE as described in this protocol (see 
Section  11.1.1) and the CRF Completion Guidelines.  In these instances, the AE corresponding 
to the ECG abnormality will be recorded on the Adverse Events CRF. For ECG abnormalities meeting the criteria of an SAE, the site must fax or email the SAE report 
including the ECG report to the Sponsor using the SAE form. 
11.5 Sponsor Serious Adverse Event Reporting Requirements  
Adverse events will be reported by the Sponsor or a third party acting on behalf of the Sponsor to 
regulatory authorities in compliance with local and regional law and established guidance.  The format of these reports will be dictated by the local and regional requirements.  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 130 of 160 All studies that are conducted within any European country will comply with European Good 
Clinical Practice Directive 2005/28/EC and Clinical Trial Directive 2001/20/EC.  All suspected unexpected serious adverse reactions (SUS ARs) will be reported, as required, to the competent 
authorities of all involved European member states. 
11.5.1.1 Expedited Reporting  
The Sponsor must inform investigators and regulatory authorities of reportable events, in 
compliance with applicable regulatory requirements, on an expedited basis (ie, within specific time frames).  For this reason, it is imperative that sites provide complete SAE information in the manner described above.  
12. QUALITY ASSURANCE AND QUALITY CONTROL  
12.1 Monitoring  
Site monitoring  shall be conducted to ensure that subject protection, study procedures, 
laboratory, study intervention administration, and data collection processes are of high quality and meet Sponsor, Good Clinical Practice (GCP )/International Conference on Harmonisation 
(ICH) and, when appropriate, regulatory guidelines. 
12.2 Audits and Inspections  
The investigator will permit study -related quality audits and inspections by the Sponsor or its 
representative(s), government regulatory authorities, and the IRB/EC of all study- related 
documents (eg, source documents, regulatory documents, data collection instruments, CRFs).  The investigator will ensure the capability for review of applicable study -related facilities.  The 
investigator will ensure that the auditor or inspector o r any other compliance or quality assurance 
reviewer is given access to all study -related documents and study- related facilities.  
Participation as an investigator in this study implies the acceptance of potential inspection by government regulatory authori ties, the IRB/EC, and the Sponsor or its representative(s).  
13. ETHICAL, FINANCIAL, AND REGULATORY CONSIDERATIONS  
This research study will be conducted according to the standards of GCP outlined in the ICH E6 Tripartite Guideline and Code of Federal Regulations ( CFR) Title 21 Part 312, applicable 
government regulations, institutional research policies and procedures and any other local applicable regulatory requirement(s).  
13.1 Institutional Review Board Approval 
The clinical study protocol, ICF, IB, available safety information, subject documents (eg, study diary), subject recruitment procedures (eg , advertisements), information about payments (ie , PI 
payments) and compensation available to the subjects and documentation evidencing the PI’s qualifications should be submitted to the IRB for ethical review and approval if required by local 
regulations, prior to the study start.  
The PI/Sponsor and/or designee will follow all necessary regulations to ensure appropriate, initial, and on-going IRB study review.  The PI/Sponsor (as appropriate) must submit and, where 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 131 of 160 necessary, obtain approval from the IRB for all subsequent protocol amendments and changes to 
the ICF.  Investigators will be advised by the Sponsor or designee whether an amendment is considered substantial or non-substantial and whether it requires submission for approval or notification only to an IRB.  
Safety updates for H3B-6545 will be prepared by the Sponsor or its representative as required for distribution to the investigator(s) and submission to the rele vant IRB.  
13.2 Regulatory Approval  
As required by local regulations, the Sponsor will ensure all legal aspects are covered, and approval of the appropriate regulatory bodies obtained, prior to study initiation.  If required, the Sponsor will also ensure that the implementation of substantial amendments to the protocol and other relevant study documents happens only after approval by the relevant regulatory authorities. 
13.3 Informed Consent  
Informed consent is a process by which a subject voluntarily confirms his or her willingness to 
participate in a particular study after having been informed of all aspects of the study that are relevant to the subject's decision to participate.  Informed consent is documented by means of a written, signed, and dated ICF. 
The ICF wi ll be submitted for approval to the IRB that is responsible for review and approval of 
the study.  Each ICF must include all of the relevant elements currently required by the FDA, as 
well as local county authority or state regulations and national require ments.  
Before recruitment and enrollment into the study, each prospective candidate will be given a full explanation of the research study.  
Once the essential information has been provided to the prospective candidate, and the 
investigator is sure that th e individual candidate understands the implications of participating in 
this research study, the candidate will be asked to give consent to participate in the study by 
signing an ICF.  A notation that a written ICF has been obtained will be made in the subject’s 
medical record.  A copy of the ICF, to include the subject’s signature, will be provided by the investigator to the subject.  
If an amendment to the protocol substantially alters the study design or the potential risks to the subject, the subject’s consent to continue participation in the study should be obtained. 
13.3.1 Confidentiality  
13.3.1.1 Subject Confidentiality  
The contents of this protocol and any amendments and results obtained during the study should 
be kept confidential by the investigator, the investigator’s staff, and the IRB/IEC and will not be disclosed in whole or in part to others, or used for any purpose other than reviewing or performing the study, without the written consent of the Sponsor.  No data collected as part of this study will be used in any written work, including publications, without the written consent of the Sponsor.  These obligations of confidentiality and non-use shall in no way diminish such obligations as set forth in either the Confidentiality Agreement or Clinical Trial Agreement (CTA) executed between the Sponsor/ Contract Research Organization ( CRO) and the 
institution/investigator.  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 132 of 160 All persons assisting in the performance of this study must be bound by the obligations of 
confidentiality and non- use set forth in either the Confidentiality Agreement or CTA executed 
between the institution/investigator and  the Sponsor/CRO. 
Confidentiality of subject’s personal data will be protected in accordance with all applicable 
global regulations. R egulations require that, in order to participate in the study, a subject must 
sign an authorization from the study that he  or she has been informed of following: 
● What protected health information (PHI) will be collected from subjects in this study.  
● Who will have access to that information and why. 
● Who will use or disclose that information.  
● That health information may be furth er disclosed by the recipients of the information, and 
that if the information is disclosed the information may no longer be protected by federal or state privacy laws.  
● The information collected about the research study will be kept separate from the subje ct’s medical records, but the subject will be able to obtain the research records after 
the conclusion of the study. 
● Whether the authorization contains an expiration date. 
● The rights of a research subject to revoke his or her authorization. 
In the event that a subject revokes authorization to collect or use his or her PHI, the investigator, by regulation, retains the ability to use all information collected prior to the revocation of subject authorization.  For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (ie, that the subject is alive) at the end of their scheduled study period. 
In compliance with ICH GCP guidelines and applicable parts of 21 CFR it is a require ment that 
the investigator and institution permit authorized representatives of the Sponsor, the regulatory 
authorities and the IRB/EC direct access to review the subject’s original medical records at the site for verification of study -related procedures a nd data.  
Measures to protect confidentiality include that only a unique study number and initials will identify subjects in the eCRF system or other documents submitted to the Sponsor.  This information, together with the subject’s date of birth, will be used in the database for subject 
identification.  Subject names or addresses will not be entered in the eCRF database system.  No material bearing a subject’s name will be kept on file by the Sponsor.  Subjects will be informed of their rights within the ICF/patient information sheet.  
13.3.1.2 Investigator and Staff Information  
Personal data of the investigators and sub-investigators may be included in the database and shall be treated in compliance with all applicable laws and regulations.  When archiving or processing personal data pertaining to the investigator or sub- investigator, all appropriate measures will be 
taken to safeguard and prevent access to this data by any unauthorized party. 
The name and telephone and fax numbers of the Medical Monitor and other contact personnel at 
the Sponsor and of the CRO(s) are listed in the Investigator Study File provided to each site. 
13.4 Financial Information  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 133 of 160 The finances for this clinical study will be subject to a separate written agreement between the 
Sponsor and applicable parties.  Any investigator financial disclosures as applicable to 21CFR Part 54 shall be appropriately provided. 
14. RESEARCH RETENTION AND DOCUMENTATION OF THE STUDY  
14.1 Amendments to the Protocol  
Amendments to the protocol shall be planned, documented and signature authorized prior to 
implementation.  
If an amendment to the protocol is required, the amendment will be originated and documented by the Sponsor or its representative.  All amendments require review and approval of all pharmaceutical companies and the PI supporting the study.  The written amendment must be reviewed and approved by the Sponsor and submitted to the IRB at the investigator’s facility for the board’s approval.  
Amendments specifically involving change to study design, risk to subject, increase to dosing or exposure, subject number increase, or addition or removal of new tests or procedures shall be reviewed and approved by the IRB of record for the investigator’s facility. 
The amendment will be submitted formally to the FDA or other regulatory authorities by the 
Sponsor as applicable and IRB/EC approval obtained, specifically when an increase to dosing or subject exposure and/or subject number has been proposed; or, when the addition or removal of an investigator is necessitated.  
Items requiring a protocol amendment with IRB and/or FDA or other regulatory authorities’ approval include, but are not limited to, the following: 
● Change to study design. 
● Risk to subject. 
● Increase to dose or subject exposure to drug. 
● Subject number increase 
● Addition or removal of tests and/or procedures 
● Addition/removal of a new investigator 
It should be further noted that, if an amendment to the protocol substantially alters the study design or the potential risks to the subjects, their consent to continue participation in the study should be obtained. 
14.2 Documentation Required to Initiate the Study  
Before the study may begin certain documentation required by FDA regulations and ICH GCP 
must be provided by the investigator.  Documents required to begin a study in the US include at a minimum, but are not limited to, the following:  
● A signed and dated confidentiality agreement 
● A signature-authorized protocol and contract 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 134 of 160 ● A copy of the official IRB approval of the study and the IRB/EC members list 
● Current curricula vitae for the PI and any associate investigator(s) who will be involved 
in the study 
● Indication of appropriate accreditation for any laboratories to be used in the study and a copy of the normal ranges for tests to be performed by that laboratory 
● Original Form FDA 1572 (Statement of Investigator), appropriately completed and signed 
● A copy of the IRB/EC-approved ICF (and patient information sheet , if applicable) 
containing permission for audit by representatives of the CRO, the Sponsor, the IRB, and the FDA and other regulatory agencies (as applicable).  
● Financial disclosure forms for all investigators listed on Form FDA 1572 (if applicable, ie, for covered trial).  
● Site qualification reports, where applicable. 
● Verification of PI acceptability  from local and/or national debarment list(s)  
14.3 Study Documentation and Storage  
The PI must maintain a list of appropriately qualified persons to whom he/she has delegated study duties and should ensure that all persons assisting in the conduct of the study are informed of their obligations.  All persons authorized to make entries and/or corrections on the eCRFs are to be included on this document.  All entries in the subject’s eCRF are to be supported by source documentation where appropriate. 
Source docume nts are the original documents, data, records, and certified copies of original 
records of clinical findings, observations, and activities from which the subject’s eCRF data are 
obtained.  These can include, but are not limited to: hospital records and cli nical and office 
charts; laboratory, medico- technical department and pharmacy records; diaries, microfiches, and 
ECG traces; copies or transcriptions certified after verification as being accurate and complete; photographic negatives, microfilm or magnetic media; X -rays; and correspondence. 
The PI and each study staff member is responsible for maintaining a comprehensive and centralized filing system (eg , regulatory binder or investigator study file [ISF]) of all study -
related (essential) documentation, sui table for inspection at any time by representatives from the 
Sponsor and/or applicable regulatory authorities.  The ISF must consist of those documents that individually or collectively permit evaluation of the conduct of the study and the quality of the data produced.   
The ISF should contain as a minimum all relevant documents and correspondence as outlined in 
ICH GCP Section 8 and 21 CFR Part 312.57, including key documents such as the IB and any amendments, protocol and any amendments, signed ICFs, copi es of completed eCRFs, IRB 
approval documents, Financial Disclosure forms, subject identification lists, enrollment logs, delegation of authority log, staff qualification documents, laboratory normal ranges, and records relating to the study drug including accountability records.   
Drug accountability records should, at a minimum, contain information regarding receipt, 
shipment, and disposition.  Each form of drug accountability record, at a minimum, should contain PI name, date drug shipped/received, quantity, and batch/code or lot number for identity 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 135 of 160 of each shipment.  In addition, all original source documents supporting entries in the eCRF must 
be maintained and be readily available.  
The Sponsor shall maintain adequate investigational product records and financial interest records as per 21CFR Part 54.6 and Part 312.57 for no less than 2 years after the last marketing application has been approved by FDA; or, in the event that the marketing application has not been approved by FDA, for no less than 2 year s after the last shipment/delivery of the drug for 
investigational use is discontinued and the FDA has been notified of the discontinuation. 
The IRB shall maintain adequate documentation/records of IRB activities as per 21CFR Part 
56.115 for at least 3 yea rs after completion of the research.  
The investigator shall maintain adequate records of drug disposition, case histories and any other study-related records as per 21 CFR Part 312.62 for no less than 2 years after the last marketing application has been approved by FDA; or, in the event that the marketing application has not been approved by FDA, for no less than 2 years after the last shipment/delivery of the drug for investigational use is discontinued and FDA has been notified of the discontinuation. 
To enable evaluations and/or audits from regulatory authorities or from the Sponsor or its 
representative, the investigator additionally agrees to keep records, including the identity of all 
participating subjects (sufficient information to link records eg, eCRFs, medical records), all 
original signed ICFs, and copies of all eCRFs, SAE Reporting forms, source documents, detailed records of treatment disposition, and related essential regulatory documents.  The documents listed above must be retained by the investigator for as long as needed to comply with national and international regulations (generally 2 years after discontinuing clinical development or after the last marketing approval).  The Sponsor or its representatives will notify the investigator(s)/institutions(s) when the study -related records are no longer required. 
If the investigator relocates, retires, or for any reason withdraws from the study, both the Sponsor and its representative should be prospectively notified.  The study records must be transferred to 
an acceptable designee, such as another investigator, another institution, or to the Sponsor.  The 
investigator must obtain the Sponsor’s written permission before disposing of any records, even if retention requirements have been met.  All IS Fs will be maintained by the Sponsor or its 
representative throughout the study and will be transferred to the Sponsor at the conclusion of the study. 
14.4 Data Collection  
The study eCRF is the primary data collection instrument for the study.  Case report forms will 
be completed using the English language and should be kept current to enable the Sponsor to review the subjects’ status throughout the course of the study. 
In order to maintain confidentiality, only study number, subject number, initials and date of birth 
will identify the subject in the eCRF system if applicable by governing laws.  If the subject’s 
name appears on any other document (eg, laboratory report), it must be obliterated on the copy of the document and replaced instead with the s ubject number and subject’s initials or allowable 
country specific subject identifying information.  The investigator will maintain a personal subject identification list (subject numbers with corresponding subject identifiers) to enable records to be iden tified and verified as authentic.  Subject data/information will be kept 
confidential and will be managed according to applicable local, state, and federal regulations. 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 136 of 160 All data requested by the eCRF system must be supported by and be consistent with the subject’s 
source documentation.  All missing data must be explained.  When a required laboratory test, assessment, or evaluation has not been done or an “Unknown” box is not an option on the eCRF, a note should be created verifying that the field was “Not D one” or “Unknown.”  For any entry 
errors made, the error(s) must be corrected, and a note explaining the reason for change should be provided. 
The investigator will electronically sign and date the subject eCRF indicating that the data in the 
eCRF has been  assessed.  Each completed eCRF will be signed and dated by the PI, once all data 
for that subject is final.  
14.5 Discontinuation of Study  
The Sponsor reserves the right to discontinue the study for medical reasons or any other reason at 
any time.  If a study is prematurely terminated or suspended, the Sponsor will promptly inform the investigators/institutions and regulatory authorities of the te rmination or suspension and the 
reason(s) for the termination or suspension.  The IRB/IEC will also be informed promptly and provided the reason(s) for the termination or suspension by the Sponsor or by the investigator/institution, as specified by the applicable regulatory requirement(s).  
The investigator reserves the right to discontinue the study should his/her judgment so dictate.  If the investigator terminates or suspends a study without prior agreement of the Sponsor, the 
investigator should inform t he institution where applicable, and the investigator/institution 
should promptly inform the Sponsor and the IRB/IEC and provide the Sponsor and the IRB/IEC with a detailed written explanation of the termination or suspension.  Study records must be retain ed as noted above.  
14.6 Disclosure and Publication Policy  
All manuscripts, abstracts, or other modes of presentation arising from the results of the study must be reviewed and approved in writing by the Sponsor in advance of submission pursuant to 
the terms and  conditions set forth in the executed CTA between the Sponsor/CRO and the 
institution/investigator.   The review is aimed at protecting the Sponsor's proprietary information 
existing either at the date of the commencement of the study or generated during the study. 
The detailed obligations regarding the publication of any data, material results, or other 
information generated or created in relation to the study shall be set out in the agreement between each investigator and the Sponsor or CRO, as appropriate.
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 137 of 160 15. REFERENCES  
American Cancer Society , 2015 
American Cancer Society. Breast cancer facts & figures 2015 -2016. Atlanta: American Cancer 
Society, Inc. 2015. 
Apone et al. , 1997 
Apone S, Lee MY, Eyre DR. Osteoclasts generate cross -linked collagen N-telopeptides (NTx) 
but not free pyridinolines when cultured on human bone. Bone. 199721:129-136.  Beslija et al. , 2009 
Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic 
breast cancer. Ann Oncol. 2009;20:1771-85. Chandarlapaty et al., 2016 
Chandarlapaty S, Chen D,  He W,  et al . Prevalence of ESR1 mutations in cell -free DNA and 
outcomes in metastatic breast cancer: a secondary analysis of the BOLERO -2 clinical trial.  
JAMA Oncol. 2016;2:1310-1315. 
Eisenhauer 
et al. , 2009 
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.  New response 
evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).  Eur J Cancer.  
2009;45(2):228-247. Available from:  http://linkinghub.elsevier.com/re trieve/pii/S0959804908008733. 
Fanning et al. , 2016 
Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, et al. Estrogen 
receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activati ng function-2 binding conformation. eLife. 2016;5: 
e12792. 
FDA, 2009 
Guidance for industry drug- induced liver injury:  Premarketing clinical evaluation.  
https://www.fda.gov/downloads/Drugs/.../guidances/UCM174090.pdf (accessed June 23, 2017) 
FDA, 2012 
Draft guidance on drug interaction studies. 
https://www.fda.gov/downloads/Drugs/Guidances/ucm292362.pdf (accessed April 19, 2017) 
FDA, 2019 
Guidance for Industry, Assessing the effects of food on drugs in INDs and NDAs – Clinical 
pharmacology considerations guidance for industry, 2019. Available from: 
https://www.fda.gov/media/121313/download (accessed July 16, 2019) 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 138 of 160 Ferlay et al. , 2013 
Ferlay J, Soerjomataram  I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and 
mortality worldwide: IARC CancerBase No 11. 2013. 
http://globocan.iarc.fr/Pages/summary_table_pop_sel.aspx (accessed December 19, 2016). 
Fribbens et al ., 2016 
Fribbens C, O'Leary B, Kilburn L, et al. Plasma ESR1 Mutations and the Treatment of Estrogen 
Receptor -Positive Advanced Breast Cancer. J Clin Oncol. 2016;34(25):2961-2968. 
doi:10.1200/JCO.2016.67.3061 
Fu et al. , 2006 
Fu HJ,  Jia LT,  Bao W,  et al. Stable knockdown of estrogen receptor alpha by vector- based RNA 
interference suppresses proliferation and enhances apoptosis in breast cancer cells. Cancer Biol 
Ther. 2006;5(7):842-7. Gomez et al. , 1995 
Gomez B, Ar
dakani S, Ju J, et al. Monoclonal antibody assay for measuring bone- specific 
alkaline phosphatase activity in serum. Clin Chem. 1995;41:1560-1566. 
Gonzalez et al. , 2020 
Gonzalez, T.L., Hancock, M., Sun, S. et al. Targeted degradation of activating estrogen receptor 
α ligand-binding domain mutations in human breast cancer. Breast Cancer Res Treat. 2020;180:611–22. https://doi.org/10.1007/s10549-020-05564-y 
Gyanchandani et al. , 2016 
Gyanchandani R, Kota KJ, Jonnalagadda AR, et al. Detection of ESR1 mutations in circulating 
cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. 
Oncotarget. 2016;8(40):66901–11. Published 2016 Aug 19. doi:10.18632/oncotarget.11383 
Jeselsohn et al. , 2014 
Jeselsohn R, Yelensky R, et al. Emergence of constitutively active estrogen receptor-α mutations 
in pretreated advanced estrogen receptor -positive breast cancer. Clin Cancer Res. 2014;20:1757-
67.  
Jukkola et al., 1997  
Jukkola A, Tahtela R, Tholix E et al. Aggressive breast cancer leads to discrepant serum levels 
of the ty pe I procollagen propeptides PINP and PICP. Cancer Res. 1997;57:5517-5520.  
Korpal et al., SABCS Poster 2017 
Korpal M, Puyang X, Furman C, et al. Development of a first- in-class oral selective ERα 
covalent antagonist (SERCA) for the treatment of ERαWT and ERαMUT breast cancer. San 
Antonio Breast Cancer Symposium. 2017; San Antonio, TX. 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 139 of 160 Li et al. , 2013 
Li S, Shen D, Shao J, et al . Endocrine-therapy- resistant ESR1 variants revealed by genomic 
characterization of breast -cancer -derived xenografts. Cell Rep. 2013;4:1116-1130. 
Lumachi e
t al., 2013 
Lumachi F, Brunello A, Maruzzo M, et al. Treatment of estrogen receptor -positive breast cancer. 
Curr Med Chem. 2013; 20:596-604. 
Malvezzi et al. , 2016 
Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 
2016 with focus on leukaemias. Annals of Oncology. 2016;27:725-731. Merenbakh -Lamin et al. , 2013 
Merenbakh -Lamin K,  Ben-Baruch N,  Yeheskel A,  et al. D538G mutation in estrogen receptor-
alpha: a novel mechanism for acquired endocrine resistance in breast cancer.  Cancer Res. 
2013;73:6856-6864. 
Moral
es et al. , 2009 
Morales L, Neven P, Timmerman D, et al. Prospective assessment of the endometrium in 
postmenopausal breast cancer patients treated with fulvestrant. Breast Cancer Res Treat. 
2009;117:77-81. 
NCI CTCAE v 4.03  
National Cancer Institute Common Terminology Criteria for Adverse Events 
https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (accessed April 13, 2017) 
NCI SEER, 2016 
National Cancer Institute Surveillance, Epidemiology, and End Result Program 
https://seer.cancer.gov/statistics/summaries.html (accessed March 5, 2017)  
Nettles et al. , 2008 
Nettles KW, Bruning JB, Gil G, et al. NFkappaB selectivity of estrogen receptor ligands revealed 
by comparative crystallographic analyses. Nat Chem Biol. 2008;4:241–7. 
Osborne et al. , 2003 
Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC -3) 
and HER2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003;95:353-61. Puyang et al., 2018 
P
uyang X, Furman C, Zheng GZ, et al. Discovery of selective estrogen receptor coval ent 
antagonists for the treatment of ERαWT and ERαMUT breast cancer. Cancer Discov. 
2018;8:1176–93. 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 140 of 160 Razavi et al., 2020 
Razavi, P., Dickler, M.N., Shah, P.D. et al. Alterations in PTEN and ESR1 promote clinical 
resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020;1:382–93. 
https://doi.org/10.1038/s43018-020-0047-1 
Robinson et al. , 2013 
Robinson DR, Wu YM,  Vats P,  Su F,  Lonigro RJ, Cao X, et al . Activating ESR1 mutations in 
hormone- resist
ant metastatic breast cancer. Nat Genet. 2013;45:1446-1451. 
Schiavon et al., 2015 
Schiavon G, Hrebien S, Garcia- Murillas I, et al. Analysis of ESR1 mutation in circulating tumor 
DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 
2015;7(313):313ra182. doi:10.1126/scitranslmed.aac7551 
Segal and Dowsett, 2014 
Segal CV & Dowsett M. Estrogen receptor mutations in breast cancer --new focus on an old 
target. Clin Cancer Res. 2014;20:1724-1726. 
Shou et al. , 2004 
Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased 
estrogen receptor -HER2/neu cross- talk in ER/HER2 -positive breast cancer. J Natl Cancer Inst. 
2004;96(12):926-35. 
Simon , 1989  
Simon R. Optima two -stage design for phase II clinical trials. C Clin Trials. 1989;10:1-10.  
Spicer and Pike , 1993 
Spicer DV
 & Pike MC. Breast cancer prevention through modulation of endogenous hormones 
Breast Cancer Res Treat. 1993;28:179-193. 
Takeshita et al. , 2016 
Takeshita T, Yamamoto Y, Yamamoto -Ibusuki M, et al. Clinical significance of monitoring 
ESR1 mutations in circulating cell- free DNA in estrogen receptor positive breast cancer 
patients. Oncotarget. 2016;7(22):32504–18. doi:10.18632/oncotarget.8839 
Tilli et al. , 2003 
Tilli MT,  Frech MS,  Steed ME,  et al. Introduction of estrogen receptor- alpha into the tTA/TAg 
conditional mouse model precipitates the development of estrogen- responsive mammary 
adenocarcinoma. Am J Pathol. 2003;163(5):1713-9. 
Toy et al., 2013 Toy W, Shen Y, Won H
, et al. ESR1 ligand- binding domain mutations in hormone -resistant 
breast cancer. Nat Genet. 2013;45:1439-1445. 
Wolff et al. , 2013 
Wolff A, Hammond E, Hicks D, Dowsett M, McShane LM, Allison KH , et al.  
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 141 of 160 American society of clinical oncology/college of american pathologists clinical practice 
guideline update.  J of Clin Oncology.  2013;31(31) :3997-4013.   
Yu et al. , 2014 
Yu M,  Bardia A,  Aceto N,  et al. Cancer therapy. Ex vivo culture of circu lating breast tumor cells 
for individualized testing of drug susceptibility. Science. 2014;345:216-220.
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 142 of 160 16. APPENDICES  
  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 143 of 160 APPENDIX  A: ECOG  PERFORMANCE STATUS CRITERIA  
 
ECOG Performance Status Scale   
Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity. Fully active, able to carry 
on all pre -disease performance without 
restriction.   
100 Normal, no complaints, no evidence of 
disease.  
 
90 Able to carry on normal activity; minor 
signs or symptoms of disease.  
1 Symptoms, but ambulatory.  Restricted in 
physically strenuous activity, but 
ambulatory and able to carry out work of a 
light or sedentary nature (eg, light 
housework, office work).   
80 Normal activity with effort; some signs or 
symptoms of disease.  
 
70 Cares for self, unable to carry on normal 
activity or to do active work.  
2 In bed < 50% of the time.  Ambulatory and 
capable of all self-care, but unable to carry 
out any work activities.  Up and about 
more than 50% of waking hours.   
60 Requires occasional assistance, but is able 
to care for most of his/her needs.  
 
50 Requires considerable assistance and 
frequent medical care.  
3 In bed > 50% of the time.  Capable of only 
limited self -care, confined to bed or chair 
more than 50% of waking hours.   
40 Disabled, requires special care and 
assistance  
 
30 Severely disabled, hospitalization 
indicated.  Death no imminent.  
4 100% bedridden.  Completely disabled.  
Cannot carry on any self -care.  Totally 
confined to bed or chair.   
20 Very sick, hospitalization indicated.  
Death not imminent.  
 
10 Moribund, fatal processes progressing 
rapidly.  
5 Dead  0 Dead  
ECOG  = Eastern Cooperative Oncology Group.   
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 144 of 160 APPENDIX  B: N EW YORK HEART ASSOCIATION (NYHA)  CLASSIFICATION OF CARDIAC 
DISEASE  
The following table presents the NYHA classification of cardiac disease.  
Class  Functional Capacity  Objective Assessment  
I Patients with cardiac disease but without resulting limitations of physical 
activity.  Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.  No objective evidence of cardiovascular disease.  
II Patients with cardiac disease resulting in slight limitation of physical activity.  They are comfortable at rest.  Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.  Objective evidence of minimal cardiovascular disease.  
III Patients with cardiac disease resulting in marked limitation of physical activity.  They are comfortable at rest.  Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.  Objective evidence of moderately severe cardiovascular disease.  
IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.  Symptoms of heart failure or the 
anginal syndrome may be present even at rest.  If any physical activity is 
undertaken, discomfort is increased.  Objective evidence of severe cardiovascular disease.  
Source:  The Criteria Committee of New York Heart Association.  Nomenclature and Criteria for Diagnosis of 
Diseases of the Heart and Great Vessels.  9th Ed. Boston, MA:  Little, Brown & Co; 1994:253 -256. 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 145 of 160 APPENDIX  C: G UIDELINES FOR WOMEN OF CHILDBEARING POTENTIAL  
Acceptable Contraception Methods:    
Women of childbearing potential, defined as all women physiologically capable of becoming 
pregnant, must use highly effective contraception during the study and for 28 days after stopping treatment.   
Highly effective contraception is defined as either:  
True Abstinence  When this is in line with the preferred and usual lifestyle of the subject.  
Periodic abstinence (eg , calendar, ovulation, symptothermal, post-
ovulation methods) and withdrawal are not acceptable methods of contraception. 
Sterilization   When a woman of childbearing potential has had surgical bilateral 
oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to study entry.  In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.  
Male Partner Sterilization  When the appropriate post-vasectomy documentation of the 
absence of sperm in the ejaculate.  
Intrauterine Device  Placement of an intrauterine device (IUD) or intrauterine system (IUS).  
A Double -Barrier Method [such as condom plus diaphragm with spermicide]  Barrier 
methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.  
Contraceptive Implant  
Oral Contraceptive  
Unacceptable Contraception Methods for women of childbearing potential include: 
● IUD progesterone T 
● Female condom  
● Natural family planning (rhythm method) or breastfeeding  
● Fertility awareness  
● Withdrawal  
● Cervical shield  
Pregnancies  
To ensure subject safety, each pregnancy in a subject on study treatment must be reported to within 24 hours of learning of its occurrence.   
The pregnancy should be followed up for 3 months after the termination of the pregnancy to 
determine outcome, incl uding spontaneous or voluntary termination, details of the birth, and 
the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 146 of 160 Pregnancy should be recorded on a Clinical Study Pregnancy Form and reported by the 
investigator.  Pregnancy follow-up should be recorded on the same form and should include an assessment of the possible relationship to the study drug of any pregnancy outcome.  Any SAE experienced during pregnancy must be reported on the SAE Report Form. 
Pregnancy outcomes must be collected for the female partners of any males who took study 
treatment in this study.  Consent to report information regarding these pregnancy outcomes should be obtained from the mother. 
The detailed contact informa tion for reporting of pregnancies is provided in the Investigator 
Study File. Women Not of Childbearing Potential are Defined as Follows:   
● Women are considered postmenopausal and not of childbearing potential if they have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (eg, age appropriate, history of vasomotor symptoms).  
● Women who are permanently sterilized (ie , bilateral tubal ligation, total hysterectomy, 
or bilateral oophorectomy, all with surgery at least 1  month before dosing).  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 150 of 160 acquisition; PD = pharmacodynamics; PG = pharamacogenetic; PK = pharmacokinetic; PT/PTT = prothrombin time/partial thromboplastin time; RECIST = Response Evaluation Criteria in Solid 
Tumors ; TSH = thyroid-stimulating hormone  
a. Informed consent must be obtained ≤28 days prior to the initiation of study treatment.  Informed consent must be obtained for pre -screening for ESR1  mutations, and the results from a 
sponsor-designated cfDNA test confirming subject eligibility must be obtained prior to signature of the informed consent form,  unless prior authorization has been received by the Sponsor, 
based on local mutation analysis -. 
b. Physical examinations will include measurements of weight and vital signs (resting heart rate [HR], blood pressure [BP], respiratory rate [RR], oral temperature).  No need to repeat physical exams on Cycle 1 Day 1 if the baseline physical exam was performed ≤72 hours.  Height will be recorded at the baseline visit onl y.  Cycle 2 and beyond, physical exam will be obtained on 
Day 1 of each cycle.   
c. A bone scan (99m-technetium-based scintigraphy, whole-body bone magnetic resonance imaging, or 18F-sodium fluoride position emission tomography) to establish a baseline should be 
performed prior to first dose of study drug (a historical bone scan performed within 6 weeks prior to the first dose is accep table), and as clinically indicated.  Lesions identified on bone scans 
should be followed with cross-sectional imaging.  
d. Triplicate 12 -lead ECGs will be collected approximately 5 minutes apart at the screening visit for all subjects.  On Day 1 of Cycles 1, 2,  3, and 4, triplicate ECGs will be collected 
approximately 5 minutes apart pre -dose and 3 hours (± 1 hour) post -dose for all subjects. Mandatory collections will be taken for both Phase 1 and Phase 2 subjects on Day 1 and Day 15 of 
Cycle 1. 12-lead safety ECGs will be performed locally from Day 1 of each cycle starting Cycle 5 till the last cycle prior to the EOT visit, and at Unscheduled visits as clinically required.  A single 12- lead safety ECG is required at a minimum.  Data from local safety ECGs should be entered into the clinical database.  At the end-of-treatment visit, 1 set of triplicate ECGs will be 
collected approximately 5 minutes apart.  If sinus bradycardia is ongoing at the EOT visit, ECGs should be obtained at least once a week until confirmation obtained that subject has returned to 60 or more beats per minute or to pre -treatment baseline value. If sinus bradycardia is observed at any point during treatment (from ECG or other clinical assessment), it is recommended 
the subject undergo a stress test per institution policy and data is recorded in the clinical database. A stress test is recommended to be done only once for each subject who has under 60 beats per minute (while on treatment) and more than a 20 percent reduction from baseline in beats per minute. The stress test should be triggered by the previous two cardiac observations at rest . 
Baseline, Cycle 1 - Cycle 4, EOT, and 28 Day Safety Follow-up visit ECGs should be collected on study specific equipment provided by ERT. Additional ECGs taken during the study 
period on local machines should also be reported in the clinical database. 
e. A 12 -lead continuous Holter will be used in Cycle 1, Days 1 and 15 [at least 1 hour prior to the first administration of the drug and continue through at least 24 hours after] for Phase 1 
subjects only (ECG and Holter monitoring grouped together in Phase 1).  For convenience, Holter monitoring may begin up to 12 hours prior to dosing on Cycle 1, Day 1 and Day 15. Holter 
monitoring will not apply to subjects  enrolled under Amendment 6 (or subsequent amendments). 
f. All concomitant medications taken within 28 days prior to Cycle 1 Day 1 and while on study treatment through 28 days post -last dose should be documented in the electronic case report 
form (eCRF).  
g. Hema tological parameters include the following laboratory tests: CBC consisting of hematocrit, hemoglobin, total white blood count (WBC) with 5 -part differential, and platelet count plus 
reticulocyte count.  Do not repeat on Cycle 1 Day 1 if it is within 72 hours of baseline.  CBCs are collected every visit before treatment.  
h. CMP panel includes the following: blood urea nitrogen (BUN), creatinine, sodium, potassium, calcium, chloride, carbon dioxide, magnesium, phosphorous, glucose, albumin, total protein, total bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase, and thyroid function tests (TSH and Free T4).  Do not 
repeat on Cycle 1 Day 1 if it is within 72 hours of baseline.  
i. PT/PTT wil l be assessed at screening by standard method at a local laboratory.  PT/PTT will be analyzed weekly during the first cycle and on Day 1 and Day 15 of all subsequent cycles and 
at the end-of-treatment visit. This must be obtained with a peripheral blood st ick.  
j. Urine testing dipstick will be done at baseline and weekly during Cycle 1.  Thereafter urine dipstick will be done on Day 1 and Day 15 of each 28-day cycle.  If abnormalities are present, microscopic testing should be done.  
k. A serum or urine pregnancy test must be performed at baseline for all women of childbearing potential (ie , pre- and perimenopausal subjects) (no need to repeat on Cycle 1 Day 1 if within 72 
hours).  For women of childbearing potential, the test will be repeated on Day 1 of each additional cycle prior to administration, at end of treatment visit and safety follow up visit (28 days (with up to +7 day window).  A negative result must be confirmed prior to administration.  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 151 of 160 l. PK blood samples will be collected for all Phase 1 subjects on Cycle 1 Day 1 and Day 15 (at time points 0 (pre -dose), 0.5 hr, 1 hr, 2 hr, 4 hr, 6 hr 8 hr, 10 hr and 24 hr post -dose) and at pre -
dose on Cycle 1 Day 8 and Day 22.  The ±1 day- window does not apply to the Day 1 and Day 15 visits.  Subjects in the food-effect portion of Phase 2 will have PK blood samples collected 
on Cycle 1 Day 15 and Cycle 1 Day 22 at time points 0 (pre -dose), 0.5, 1, 2, 4, 6, 8, 10, and 24 hr post -dose.  Subjects in the food -effect cohort will be randomly assigned to receive the 
Cycle 1 Day 15 dose of H3B-6545 in a fed or fasted state.  Each subject will then receive the Cycle 1 Day 22 dose in the reverse/untried state. At least  sparse sampling for PK (3 time points 
per subjects) will be performed on Day 15 for the Phase 2 subjects not enrolled in the food-effect sub -study following one of three schedules, assigned sequentially: Schedule 1:  pre -dose (0 
hr), 0.5 hr, and 6 hr, Schedule 2:  pre -dose (0 hr), 2 hr, 8 hr, or Schedule 3:  1 hr, 4 hr, 24 hr.  As this is a first -in-human clin ical trial and no prior human pharmacokinetics data are available, 
it is essential that the clinical staff take the blood samples for PK analysis as close as possible to the scheduled time point.  This should help improve the accuracy of the PK modeling and 
minimize the variability around the PK estimates for H3B-6545.  The exact date and time of the trial therapy administration must be recorded.  The exact time and date of the blood draw 
must be recorded.  A protocol deviation will be reported only when a PK time point is not collected (missing) or blood is drawn on the wrong study day.  
For subjects enrolled under Amendment 6 (or subsequent amendments), PK samples will be collected on Cycle 1 Days 1 and 15 at pre-dose (0 hr) and at 1, 2, 4, and 6 hr post -dose.  
m. Archival tumor samples will be requested prior to the subject’s first dose.  Material should be provided as a tissue block or 15 unstained slides.  
n. Subjects will be restaged according to RECIST 1.1 at 8-week intervals  (± 1 week) until radiologic diseas e progression or starting a new cancer therapy. All study imaging for tumor 
assessments will be sent to an imaging core laboratory designated by the Sponsor for review of quality and archived for potential independent review.  
o. Tumor assessments will only be  done in subjects who have not previously demonstrated disease progression in the study unless completed within the previous 4 weeks.   
p. In addition to prescreening, screening, whole blood for cell -free DNA (nucleic acids) will be collected at Cycle 1 Day 1 and Day 15 and at the same day (or as close as possible) to each 
tumor assessment, that is, approximately every 8 weeks after Cycle 1 Day 1. Only 1 tube of 10 mL of whole blood is needed at each time point, except at prescreening, screening, Cycle 1 
Day1, and EoT, where 2 tubes of 10 mL of whole blood are required.  
q. Blood for CTCs in Phase 1 only. All biomarkers should optimally be collected pre -dose.  
r. The ±1 assessment window for Cycle 1 Day 15 does not apply to Phase 2 subjects participating in the food ef fect study.  
s. Subject must have at least one biopsiable lesion in the Phase 1 portion.  In Phase 2, subjects must also have either (a) at least 1 measurable lesion as per RECIST 1.1, or (b) at least one predominantly lytic bone lesion.  Subjects must be willing to undergo tumor biopsies prior to treatment and on Cycle 2 Day 1.  In the Phase 2 part of the trial, subjects with bone -only 
disease, or subjects for whom a biopsy is contra -indicated, may opt out of providing tumor biopsies following investigator concern and direct discussion and approval from Sponsor The 
second biopsy must be acquired during the first week of Cycle 2 (Cycle 2 Day 1-Cycle 2 Day 8).  The subject must have received at least 7 days of consecutive dosing prior to collection of the second biopsy.  The window for collection of the Cycle 2 biopsy may be extended if needed in order to ensure 7 consecutive days of dosing prior to collection.
 
For subjects enrolled under Amendment 6 (or subsequent amendments), a recent archival tumor tissue obtained within 6 months prior to enrollment or a fresh tumor biopsy must be provided. A second biopsy after initiating trial therapy is not required.  
t. Biomarkers of bone turn-over will be collected at Cycle 1 Day 1 ( any time during screening up to pre -dose) , Cycle 2 Day 15 and Cycle 4, Day 1 and EOT.  A total of 6 mL of blood will 
be collected in a serum separating tube at each visit.  There can be an important circadian rhythm variation of these markers; samples should thus optimally be collected after fasting  in the 
morning (between 8:00 and 10:00 am) and specimen collection should be consistent during study visits.  
u. Transvaginal ultrasound will be performed during the screening period and at Cycle 4 Day 1 (±10 days), and every 24 weeks aft er that, as long as the subject is on study treatment; only for 
subjects who are part of the endometrium safety sub-study.   
v. All subjects will undergo the end-of-treatment assessments listed within 28 days after treatment ends.   
w. Following progression, all subjects will be followed for survival at least every 12 weeks  from EOT visit .  The follow -up can be done by telephone call at the investigator’s discretion.  
x. Subjects must be followed for AEs for 28 calendar days after the last dose and complete a safety follow -up visit on the 28th day (with up to + 7 day window). During the safety follow -up 
visit, the following should be obtained: vital signs, hematological and CMP laboratory parameters and triplicate ECGs on ERT provided study equipment.  
y. Missed visits:  If a scheduled p rotocol visit is missed or rescheduled for any reason, all clinic visits will be scheduled based on the subject’s Cycle 1 Day 1 date. Missed safety assessments 
are to be performed at the subsequent visit when patient resumes study treatment.  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 152 of 160 Dose interruption:  During or immediately following a dose interruption, the protocol requires that study visit take place in order for the completion of required safety assessments. PK/PD 
samples missed due to dose interruptions do not have to be retroactively  collected.  
Unscheduled visit:  Safety assessments that are obtained outside of the routine visits are recorded in the eCRF under “Unsche duled Visit” using the actual visit date.  
z. Subjects may discontinue Day 15 visits for all cycles beyond cycle 4. 
 
   
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 153 of 160 APPENDIX  F: E XTENSION PHASE  
 
Extension Phase will begin for subjects still on treatment at the time of the data cutoff for primary analysis 
 
Procedure  TreatmentA EoTN Safety Follow -Up 
Vital signs and weightB X   
Physical examinationC X X  
ECOG performance status  X X  
12-Lead ECGD X X  
Echocardiogram or MUGA scanE As clinically indicated  As clinically indicated   
Hematology and clinical chemistry (local lab)F X X  
Urine dipstick testingG X X  
Pregnancy testH X X  
Tumor assessments (CT/MRI)I As per local standard of care but not less 
frequently than every 12 weeks or earlier if 
clinically indicated    
Bone ScanJ As clinically indicated    
Brain scan (CT/MRI)K As clinically indicated    
Study Treatment  28 Day cycle    
Concomitant medicationsL X X X 
AEs/SAEsM X X X 
AE = adverse event; BP = blood pressure; CT = computed tomography; ECG = electrocardiogram; EoT=end of treatment assessment;  HR = heart rate; LVEF = left 
ventricular ejection fraction ; MRI=magnetic resonance imaging; MUGA = multiple -gated acquisition; RR = respiratory rate;  SAE -serious adverse event . 
 
A. Efforts should be made to conduct study visits on the day scheduled ( Cycle X Day 1 ±3 days) . The study visit (and safety assessments) still needs to occur regardless of a 
study medication hold per the visit schedule.   
B. Assessments will include vital signs (resting BP [including date and time of measurement], HR, RR and body temperature) and weigh t.  
C. A symptom -directed physical examination during the study, as clinically indicated.  
D. Single 12 -lead ECG . Subjects are suggested to be in the recumbent position for a period of 5 minutes prior to obtaining ECG.  
E. An echocardiogram or MUGA scan to assess LVE F will be performed as clinically indicated  
F. Clinical laboratory assessments will be conducted at a local laboratory. Clinical chemistry and hematology results should be reviewed prior to administration of study 
drug for all cycles. Assessments may be perfo rmed within 72 hours prior to the visit.  
G. Urine dipstick testing for subjects should be performed preferably at the investigational site (but may be performed locally by the primary care physician or a local 
laboratory if the subject does not have to come f or a visit to the site).  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG 2022 Page 154 of 160 H. A serum or urine pregnancy test will be performed at Day 1 of every cycle, and at the EoT assessment in women of childbearing potential (ie, premenopausal and 
perimenopausal women who have been amenorrheic for less than 12 months).  
I. After the data cutoff for the primary analysis: Tumor assessments using contrast -enhanced CT of the chest and contrast -enhanced CT or MRI of the abdomen, pelvis and 
other areas of known disease at screening or newly suspected disease should be performed as per local standard of care but not less frequently than every 12 weeks  or 
earlier if clinically indicated .  The same methodology (CT or MRI) and scan acquisition techniques that were used for the assessment during the Study Treatment Phase  
should be used after the data cutoff for the primary analysis.   
J. A bone scan to assess bone metastases should be performed as  clinically indicated.  
K. Brain scans should be performed as clinically indicated.  
L. Concomitant medications will be recorded until 28 days after last dose  
M. Subjects must be followed for AEs for 28 calendar days after the last dose and complete a safety follow -up visit on the 28th day (with up to + 7 day window).  
N. Tumor assessments will only be done in subjects who have not previously demonstrated disease progression in the study unless completed within the previous 4 weeks.  
 
 
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG  2022 Page 155 of 160 APPENDIX  G: R ESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RECIST)  
VERSION  1.1 
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.  New response evaluation criteria in 
solid tumours: revised RECIST guideline (version 1.1).  Eur J Cancer.  2009;45(2):228 -47. 
  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG  2022 Page 156 of 160 APPENDIX  H: C ONCOMITANT MEDICATIONS  
Combination administration of study drugs could result in DDI that could potentially lead to 
reduced activity or enhanced toxicity of the concomitant medication and/or H3B-6545.  
Use of antacids is allowed . 
The use of palonosetron, prochlorperazine, promet hazine, and cyclizine for management of 
nausea and vomiting is also allowed.  The use of ondansetron and granisetron is not permitted 
because of their potential to prolong QT interval 
Herbal preparations/medications are not allowed throughout the study; thus, the subject should 
stop using herbal medications 7 days prior to first dose of H3B-6545.  These herbal medications include, but are not limited to:  St. John’s wort, kava, ephedra (ma huang), gingko biloba, 
DHEA, yohimbe, saw palmetto, and ginseng.   
The following list of prohibited medications is based on the Oncology Clinical Pharmacology 
Drug -Drug Interaction Database (release date: 29 Oct 2012), which was compiled from the 
Indiana University School of Medicine’s “Clinically Relevant” Table and suppl emented with the 
FDA Draft Guidance for Industry, Drug Interaction Studies – Study Design, Data Analysis, and 
Implications for Dosing and Labeling (February 2012).  These lists are not comprehensive and are only meant to be used as a guide.  Please contact  the medical monitor with any questions.  
  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG  2022 Page 157 of 160 List of prohibited medications (including but not limited to:)  
Category  Drug Name  
Strong CYP3A4 inhibitors 
and inducers Carbamazepine, clarithromycin, conivaptan, itraconazole, ketoconazole, nefazodone, phenobarbital, phenytoin, posaconazole, rifabulin, rifampin, telithromycin, voriconazole 
Strong CYP3A4 inhibitors Clarithromycin, conivaptan, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, voriconazole,  
Strong CYP3A4 inducers  Carbamazepine phenobarbital, phenytoin, rifabulin, rifampin,  St. John’s wort 
P-gp inhibitors1 Amiodarone, cyclosporine, dronedarone, ranolazine, verapamil  
CYP2C9 substrates with narrow therapeutic index
2 
(NTI)  Phenytoin, warfarin  
CYP2C19 substrates with NTI Diazepam, amitriptyline, phenytoin  
CYP3A substrates with NTI  Alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus 
P-gp substrate with NTI Digoxin 
BCRP substrate with NTI  Sulfasalazine, methotrexate  
Medications with a known  
risk for QT prolongation See Appendix I  
BCRP  = breast cancer resistance protein; CYP  = cytochrome P450; P -gp = P-glycoprotein.  
1. P-gp inducers already listed as CYP3A4 inducers.  
2. Narrow therapeutic index drugs are drugs where small differences in dose or blood concentration may lead 
to serious therapeutic failures and/or adverse drug reactions that are life -threatening or result in persistent 
or significant disabil ity or incapacity.  
  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG  2022 Page 158 of 160 APPENDIX  I: D RUGS THAT PROLONG QT INTERVAL AND/OR INDUCE TORSADES DE 
POINTES  
This is not a comprehensive list.  A complete list may be found in Woosley, RL and Romero, 
KA, QTdrugs List, Accession Date, AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, 
AZ  85755 and updated at the following Web address: http://crediblemeds.org . 
 
Antiarrhythmics  
Amiodarone Disopyramide Dofetilide  
Ibutilide  
Procainamide Quinidine  
Sotalol  
 
Antibiotics  
Clarithromycin Erythromycin Gatifloxacin  
Moxifloxacin  
Sparfloxacin   
Antipsychotics  
Chlorpromazine Haloperidol Mesoridazine  
Pimozide Risperidone  
Thioridazine  
Ziprasidone  
Antidepressants  
Amitriptyline  
Desipramine  
Doxepin  
Imipramine  
Maprotiline  
Venlafaxine  
Antifungals (azoles)   
Ketoconazole  
Itraconazole  
Antimalarials  
Chloroquine  
Halofantrine   
Antiemetics  
Dolasetron  
Domperidone  
Droperidol  
Ondansetron  
Tropisetron   
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG  2022 Page 159 of 160 APPENDIX  I: D RUGS THAT PROLONG QT INTERVAL AND/OR INDUCE TORSADES DE 
POINTES  
This is not a comprehensive list.  A complete list may be found in Woosley, RL and Romero, 
KA, QTdrugs List, Accession Date, AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, 
AZ  85755 and updated at the following Web address: http://crediblemeds.org . 
 
Antihistamines  
Astemizole  
Terfenadine  
Alimemazine  
Hydroxyzine  
Diphenhydramine  
Miscellaneous  
Arsenic trioxide  
Bepridil Methadone  
Pentamidine  
Cisapride  
Tacrolimus  
 
  
 
CONFIDENTIAL  
STUDY DRUG :  H3B -6545 
PROTOCOL AMENDMENT 9:  29 AUG  2022 Page 160 of 160 APPENDIX  J: S ECURITY OF THE SAMPLES , USE OF THE SAMPLES , AND RETENTION OF THE 
SAMPLES  
Sample processing, for example, DNA and/or RNA extraction, genotyping, sequencing, or other 
analysis, will be performed by a laboratory under the direction of the Sponsor. Processing, analysis, and storage will be performed at a secure laboratory facility to protect the validity of the data and maintain subject privacy.  Samples will only be used  for the purposes described in 
this protocol.  Laboratories contracted to perform the analysis on behalf of the Sponsor will not retain rights to the samples beyond those necessary to perform the specified analysis and will not transfer or sell those samples.  The Sponsor will not sell the samples to a third party. 
Samples will be stored for up to 15 years after the completion of the study (defined as 
submission of the clinical study report to the appropriate regulatory agencies).  At the end of the 
storage period, samples will be destroyed.  Samples may be stored longer if a health authority (or medicinal product approval agency) has active questions about the study.  In this special circumstance, the samples will be stored until the questions have been adequately addressed.  
It is possible that future research and technological advances may identify genomic variants of interest or allow alternative types of genomic analysis not foreseen at this time. Because it is not possible to prospectively define every avenue of future testing, all samples collected will be 
single or double coded (according to the ICH E15 guidelines) in order to maintain subject privacy.
 